UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 10-Q

(Mark One)

☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

□ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to _____

Commission file number: 000-53316

SOBR Safe, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation or organization)

26-0731818 (I.R.S. Employer Identification No.)

885 Arapahoe Road

Boulder, CO

(Address of principal executive offices)

80302

(Zip Code)

(844) 762-7723

Registrant's telephone number, including area code

TransBiotec, Inc.

(Former name, address, if changed since last report)

(Former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of	Trading	Name of each exchange
each class	Symbol(s)	on which registered
None	None	None

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, \$0.00001 par value (Title of class)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes \boxtimes No \square

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (\S 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes \boxtimes No \square

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer		Accelerated filer	
Non-accelerated filer	\boxtimes	Smaller reporting company	X
		Emerging growth company	

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes 🗆 No 🗵.

Applicable only to issuers involved in bankruptcy proceedings during the preceding five years:

Indicate by check mark whether the registrant filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes \Box No \Box

Applicable only to corporate issuers:

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date. As of November 16, 2020, there were 20,046,847 shares of common stock, \$0.00001 par value, issued and outstanding.

SOBR SAFE, INC.

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION

<u>ITEM 1</u>	Condensed Consolidated Financial Statements	3
ITEM 2	Management's Discussion and Analysis of Financial Condition and Results of Operations	35
ITEM 3	Quantitative and Qualitative Disclosures About Market Risk	45
ITEM 4	Controls and Procedures	45
<u>PART II -</u>	OTHER INFORMATION	
ITEM 1	Legal Proceedings	46
ITEM 1A	Risk Factors	46
ITEM 2	Unregistered Sales of Equity Securities and Use of Proceeds	46
ITEM 3	Defaults Upon Senior Securities	46
ITEM 4	Mine Safety Disclosures	47
ITEM 5	Other Information	47
ITEM 6	Exhibits	48

PART I – FINANCIAL INFORMATION

Forward-Looking Statement Disclaimer

This Quarterly Report includes forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements are based on management's beliefs and assumptions, and on information currently available to management. Forward-looking statements include the information concerning our possible or assumed future results of operations set forth under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations." Forward-looking statements also include statements in which words such as "expect," "anticipate," "intend," "plan," "believe," "estimate," or similar expressions are used.

Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties, and assumptions. Our future results and shareholder values may differ materially from those expressed in these forward-looking statements. Readers are cautioned not to put undue reliance on any forward-looking statements.

Reverse Stock Split

At the open of market on June 8, 2020, our 1-for-33.26 reverse split of our common stock went effective with OTC Markets. As a result, all common stock share amounts, as well as share amounts and exercise and conversion prices in derivative security instruments have been adjusted to reflect the reverse stock split.

ITEM 1 Condensed Consolidated Financial Statements

The balance sheets as of September 30, 2020 and December 31, 2019, the statements of operations for the three and nine months ended September 30, 2020 and 2019, the statements of changes in stockholders' equity for the three and nine months ended September 30, 2020 and 2019, and the statements of cash flows for the nine months ended September 30, 2020 and 2019, follow. The unaudited condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. All such adjustments are of a normal and recurring nature.

SOBR Safe, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS

		otember 30, 2020 Inaudited)		cember 31, 2019 Audited)
SSETS				
Current assets				
Cash	\$	979,641	\$	681,75
Prepaid expenses		8,060		9,054
Total current assets		987,701		690,81
Property and equipment, net of accumulated depreciation of \$5,083 at September 30, 2020		42,642		
SOBR Safe Intellectual Technology, net of accumulated amortization of \$128,488 at September 30, 2020		3,726,187		
Other assets		8,680		
Total Assets	\$	4,765,210	\$	690,81
ABILITIES & STOCKHOLDERS DEFICIT Current liabilities Accounts payable	\$	95,372	\$	213.88
Accounts payable Accrued expenses	φ	270,743	φ	419,83
Accrued interest payable		167,395		674,04
Related party payables		1,354		905,44
Accrued dividends payable		161,880		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Derivative liabilities		-		60,65
Common stock subscriptions payable		100,126		79,62
Preferred stock subscriptions payable		2,700,000		1,000,00
Notes payable - current - related parties		1,496,999*		760,88
* Includes unamortized debt discount related to detached				
warrants of none and \$8,656 at September 30, 2020 and December 31, 2019, respectively				
Notes payable - current - non-related parties		145,848		169,57
Total current liabilities		5,139,717		4,283,93
Total Liabilities		5,139,717		4,283,93
Stockholders' Deficit				
Series A-1 Convertible Preferred stock, \$0.00001 par value; 2,000,000 shares authorized,				
no shares issued and outstanding				
as of September 30, 2020 and December 31, 2019 Common stock, \$0.00001 par value;		-		
100.000 shares authorized;				
20,046,424 and 6,452,993 shares issued and outstanding				
as of September 30, 2020 and December 31, 2019, respectively, after 1-for-33.26 reverse stock split		201		(
Additional paid-in capital		48,250,387		15,971,39
Accumulated deficit		(48,571,733)		(19,511,16
Total SOBR Safe, Inc. stockholders' deficit		(321,145)		(3,539,71
Noncontrolling interest		(53,362)		(53,41
		(374,507)		(3,593,12
Total Stockholders' Deficit		<u> </u>		

The accompanying notes are an integral part of the condensed consolidated financial statements.

SOBR Safe, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	For The Thr	ee Months Ended	For The Nine Months Ended			
	September 30 2020), September 30, 2019	September 30, 2020	September 30, 2019		
	(Un	audited)	(Unau			
Revenues	\$	- \$ -	\$ -			
Operating expenses:						
General and administrative	191,58	9 89,481	400,127	239,978		
Stock-based compensation expense			41,302	-		
Management salaries and consulting fees	352,26	6 -	1,103,828	-		
Research and development	152,12	3	309,403			
Total operating expenses	695,97	8 89,481	1,854,660	239,978		
Loss from operations	(695,97	8) (89,481) (1,854,660)	(239,978)		
Other income (expense):						
Loss on extinguishment of debt, net			(269,144)	-		
Gain on fair value adjustment - derivatives		- 200	60,650	3,400		
Interest expense	(41,62	2) (126,825) (107,253)	(269,619)		
Amortization of interest - beneficial conversion feature			(1,407,675)	(5,920)		
Asset impairment adjustment			(25,320,555)			
Total other expense, net	(41,62	2) (126,625)) (27,043,977)	(272,139)		
Loss before provision for income taxes	(737,60	0) (216,106) (28,898,637)	(512,117)		
Provision for income taxes			-	-		
Net loss	(737,60	0) (216,106)) (28,898,637)	(512,117)		
Net (income) loss attributable to noncontrolling interest	(9	8) 763	(48)	2,348		
Net loss attributable to SOBR Safe, Inc.	(737,69	8) (215,343)) (28,898,685)	(509,769)		
Accrued dividends on convertible preferred stock	(161,88	0) -	(161,880)	-		
Net loss attributable to common stockholders	\$ (899,57) \$ (29,060,565)	\$ (509,769)		
Basic and Diluted Loss per Common Share	\$ (0.0			\$ (0.11)		
	* (0.0	.) 🗧 (0.01	· <u>+ (2.23</u>)	÷ (0.11)		
Weighted average number of common shares outstanding	20,046,42	4 4,965,945	13.030.845	4,618,807		
weighted average number of common shares outstanding	20,040,42	4,203,943	15,050,845	4,010,007		

The accompanying notes are an integral part of the condensed consolidated financial statements.

SOBR Safe, Inc. CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)

	Commor	n Stock	Preferred	d Stock			Stockholders' Equity		Total
	Shares	Amount \$0.00001 (Par)	Shares	Amount (\$0.00001 Par)	Additional Paid-in Capital	Accumulated Deficit	(Deficit) SOBR Safe, Inc.	Noncontrolling Interest	Stockholders' Equity (Deficit)
Balances at									
January 1, 2019	3,510,255	\$ 35	1,388,575	\$ 14	\$14,888,941	\$ (18,262,136)	\$ (3,373,146)	\$ (50,285)	\$ (3,423,431)
Common		¢ 55	1,000,070	<u>φ 11</u>	<u>\$11,000,711</u>	<u> </u>	<u> </u>	<u> </u>	ф (0,120,101)
stock issued for cash	1,065,982	11	-	-	38,989	-	39,000	-	39,000
Paid-in									
capital - fair value of stock									
warrants granted	-	-	-	-	22,665	-	22,665	-	22,665
Paid-in									
capital - gain on related									
party debt conversion	_	-	_	_	8,113	_	8,113	-	8,113
Net loss for					0,115	(120.200)		(7(7)	
the period Balances at						(138,289)	(138,289)	(767)	(139,056)
March 31, 2019	4,576,236	\$ 46	1,388,575	\$ 14	\$14,958,708	\$ (18,400,425)	\$ (3,441,657)	\$ (51,052)	\$ (3,492,709)
Paid-in capital-fair value of stock									
warrants granted	-	-	-	-	12,365	-	12,365	-	12,365
Paid-in capital-gain on related					,		,		,
party debt conversion	-	-	-	-	7,409	_	7,409	-	7,409
Net loss for					, í	(156 127)	, in the second s	(010)	, i i i i i i i i i i i i i i i i i i i
the period Balances at						(156,137)	(156,137)	(818)	(156,955)
June 30, 2019	4,576,236	\$ 46	1,388,575	\$ 14	\$14,978,482	\$ (18,556,562)	\$ (3,578,020)	\$ (51,870)	\$ (3,629,890)
Common stock issued for accrued									
executive compensation	420,926	4	_	_	59,496	_	59,500	-	59,500
Common stock issued due to stock	.20,,20				0,,,,,,		27,200		27,200
warrants exercise	1,038,339	11	-	-	146,763	-	146,774	-	146,774
Common stock issued upon									
conversion of convertible preferred stock						-		-	-
to common stock	417,491	4	(1,388,575)	(14)	(1,329,551)	_	(1,329,561)	_	(1,329,561)
Paid-in capital - fair value of stock	,		(1,000,070)		(1,02),001)		(1,027,001)		(1,027,001)
warrants granted	-	-	-	-	19,505	-	19,505	_	19,505
Paid-in capital - gain on related party executive compensation									
conversion	-	-	-	-	535,500	-	535,500	-	535,500

Paid-in capital - gain on related party debt conversion	_	-	-	-	13,071	_	13,071	-	13,071
Paid-in capital - gain on related party preferred stock									
conversion	-	-	-	-	1,329,561	-	1,329,561	-	1,329,561
Net loss for the period Balances at			<u> </u>			(215,343)	(215,343)	(763)	(216,106)
September 30, 2019	6,452,993	<u>\$65</u>		<u>\$ -</u>	<u>\$15,752,827</u>	<u>\$ (18,771,905</u>)	<u>\$ (3,019,013)</u>	<u>\$ (52,633</u>)	<u>\$ (3,071,646)</u>

Table of Contents

Balances at January 1, 2020	6,452,993	\$ (5 -		s	\$15,971,392	\$(19,511,168)	\$ (3,539,711)	\$ (53 410)	\$ (3.503.121)
Common stock issued for	0,432,993	<u> </u>		-	<u>ə -</u>	\$15,971,592	<u>\$(19,511,108</u>)	<u>\$ (3,339,711</u>)	<u>\$(53,410</u>)	<u>\$ (3,593,121)</u>
compensation	601			-	-	20,800	-	20,800	-	20,800
Common stock issued due to						,		,		,
stock warrants exercise	454,097		4 -	-	-	65,724	-	65,728	-	65,728
Common stock issued to										
settle related party payables	214,883		2 -	-	-	493,072	-	493,074	-	493,074
Common stock issued to										
settle accounts payable and										
accrued expenses Common stock issued to	38,323			-	-	92,385	-	92,385	-	92,385
settle related party debt	648,739		6.			826,958		826,964		826,964
Common stock issued to	040,739		0 .	-	-	820,938	-	820,904	-	820,904
settle non-related party debt	70,448		1 .	_	_	166,525	-	166,526	-	166,526
Paid-in capital - fair value of	70,440		1			100,525		100,520		100,520
stock options vested	-			_	-	39,450	-	39,450	-	39,450
Paid-in capital - gain on						55,100		57,100		55,100
related party debt conversion	-			-	-	124,291	-	124,291	-	124,291
Paid-in capital - gain on										
related party payables										
conversion	-			-	-	221,557	-	221,557	-	221,557
Paid-in capital - loss on										
related party debt										
extinguishment	-			-	-	116,893	-	116,893	-	116,893
Paid-in capital - beneficial										
conversion feature	-			-	-	174	-	174	-	174
Net loss for the period			<u> </u>	-			(450,023)	(450,023)	149	(449,874)
Balances at March 31, 2020	7,880,084	\$	78 -	-	\$ -	\$18,139,221	\$(19,961,191)	\$ (1,821,892)	\$(53,261)	\$ (1,875,153)
Common stock issued to										
Common stock issued to settle accounts payable and										
Common stock issued to settle accounts payable and accrued expenses	121,072		2 .	_	_	173,290	-	173,292	-	173,292
settle accounts payable and	121,072		2 -	-	-	173,290	-	173,292	-	173,292
settle accounts payable and accrued expenses Common stock issued to settle related party payables	121,072 45,268		2 -	-	-	173,290 86,739	-	173,292 86,740	-	173,292 86,740
settle accounts payable and accrued expenses Common stock issued to				-	-	, í		, i i i i i i i i i i i i i i i i i i i	-	
settle accounts payable and accrued expenses Common stock issued to settle related party payables Common stock issued for asset purchase		12	1 -	-	-	, í	-	, i i i i i i i i i i i i i i i i i i i	-	
settle accounts payable and accrued expenses Common stock issued to settle related party payables Common stock issued for asset purchase Paid-in capital - beneficial	45,268	12	1 -	-		86,739 27,119,880	-	86,740 27,120,000		86,740 27,120,000
settle accounts payable and accrued expenses Common stock issued to settle related party payables Common stock issued for asset purchase Paid-in capital - beneficial conversion feature	45,268	12	1 -	-		86,739	-	86,740		86,740
settle accounts payable and accrued expenses Common stock issued to settle related party payables Common stock issued for asset purchase Paid-in capital - beneficial conversion feature Paid-in capital - fair value of	45,268	12	1 -	-	-	86,739 27,119,880 1,407,501		86,740 27,120,000 1,407,501	-	86,740 27,120,000 1,407,501
settle accounts payable and accrued expenses Common stock issued to settle related party payables Common stock issued for asset purchase Paid-in capital - beneficial conversion feature Paid-in capital - fair value of stock warrants granted	45,268	12	1 -	-	-	86,739 27,119,880		86,740 27,120,000	-	86,740 27,120,000
settle accounts payable and accrued expenses Common stock issued to settle related party payables Common stock issued for asset purchase Paid-in capital - beneficial conversion feature Paid-in capital - fair value of stock warrants granted Paid-in capital - gain on	45,268	12	1 -	-	-	86,739 27,119,880 1,407,501		86,740 27,120,000 1,407,501	-	86,740 27,120,000 1,407,501
settle accounts payable and accrued expenses Common stock issued to settle related party payables Common stock issued for asset purchase Paid-in capital - beneficial conversion feature Paid-in capital - fair value of stock warrants granted Paid-in capital - gain on related party payables	45,268	12	1 -	-	-	86,739 27,119,880 1,407,501 695,454		86,740 27,120,000 1,407,501 695,454	-	86,740 27,120,000 1,407,501 695,454
settle accounts payable and accrued expenses Common stock issued to settle related party payables Common stock issued for asset purchase Paid-in capital - beneficial conversion feature Paid-in capital - fair value of stock warrants granted Paid-in capital - gain on related party payables conversion	45,268	12	1 -	-	-	86,739 27,119,880 1,407,501		86,740 27,120,000 1,407,501	-	86,740 27,120,000 1,407,501
settle accounts payable and accrued expenses Common stock issued to settle related party payables Common stock issued for asset purchase Paid-in capital - beneficial conversion feature Paid-in capital - fair value of stock warrants granted Paid-in capital - gain on related party payables conversion Paid-in capital - loss on	45,268	12	1 -	-	-	86,739 27,119,880 1,407,501 695,454		86,740 27,120,000 1,407,501 695,454	-	86,740 27,120,000 1,407,501 695,454
settle accounts payable and accrued expenses Common stock issued to settle related party payables Common stock issued for asset purchase Paid-in capital - beneficial conversion feature Paid-in capital - fair value of stock warrants granted Paid-in capital - gain on related party payables conversion Paid-in capital - loss on extinguishment of	45,268	12	1 -	-	-	86,739 27,119,880 1,407,501 695,454 50,741		86,740 27,120,000 1,407,501 695,454 50,741	-	86,740 27,120,000 1,407,501 695,454 50,741
settle accounts payable and accrued expenses Common stock issued to settle related party payables Common stock issued for asset purchase Paid-in capital - beneficial conversion feature Paid-in capital - fair value of stock warrants granted Paid-in capital - gain on related party payables conversion Paid-in capital - loss on extinguishment of convertible notes	45,268	12	1 -	-	-	86,739 27,119,880 1,407,501 695,454		86,740 27,120,000 1,407,501 695,454	-	86,740 27,120,000 1,407,501 695,454
settle accounts payable and accrued expenses Common stock issued to settle related party payables Common stock issued for asset purchase Paid-in capital - beneficial conversion feature Paid-in capital - fair value of stock warrants granted Paid-in capital - gain on related party payables conversion Paid-in capital - loss on extinguishment of convertible notes Paid-in capital - fair value of	45,268 12,000,000 - - -	12	1 - 	-	-	86,739 27,119,880 1,407,501 695,454 50,741 273,462	-	86,740 27,120,000 1,407,501 695,454 50,741 273,462	-	86,740 27,120,000 1,407,501 695,454 50,741 273,462
settle accounts payable and accrued expenses Common stock issued to settle related party payables Common stock issued for asset purchase Paid-in capital - beneficial conversion feature Paid-in capital - fair value of stock warrants granted Paid-in capital - gain on related party payables conversion Paid-in capital - loss on extinguishment of convertible notes Paid-in capital - fair value of stock options vested	45,268	12	1 -	-	-	86,739 27,119,880 1,407,501 695,454 50,741	-	86,740 27,120,000 1,407,501 695,454 50,741 273,462 257,482	-	86,740 27,120,000 1,407,501 695,454 50,741 273,462 257,482
settle accounts payable and accrued expenses Common stock issued to settle related party payables Common stock issued for asset purchase Paid-in capital - beneficial conversion feature Paid-in capital - fair value of stock warrants granted Paid-in capital - gain on related party payables conversion Paid-in capital - loss on extinguishment of convertible notes Paid-in capital - fair value of stock options vested Net loss for the period	45,268 12,000,000 - - - - -			-		86,739 27,119,880 1,407,501 695,454 50,741 273,462 257,482	- - - - (27,710,964)	86,740 27,120,000 1,407,501 695,454 50,741 273,462 257,482 (27,710,964)		86,740 27,120,000 1,407,501 695,454 50,741 273,462 257,482 (27,711,163)
settle accounts payable and accrued expenses Common stock issued to settle related party payables Common stock issued for asset purchase Paid-in capital - beneficial conversion feature Paid-in capital - fair value of stock warrants granted Paid-in capital - gain on related party payables conversion Paid-in capital - loss on extinguishment of convertible notes Paid-in capital - fair value of stock options vested	45,268 12,000,000 - - -	12 \$ 20		-	-	86,739 27,119,880 1,407,501 695,454 50,741 273,462	-	86,740 27,120,000 1,407,501 695,454 50,741 273,462 257,482 (27,710,964)	-	86,740 27,120,000 1,407,501 695,454 50,741 273,462 257,482 (27,711,163)
settle accounts payable and accrued expenses Common stock issued to settle related party payables Common stock issued for asset purchase Paid-in capital - beneficial conversion feature Paid-in capital - fair value of stock warrants granted Paid-in capital - fair value of stock warrants granted Paid-in capital - loss on extinguishment of convertible notes Paid-in capital - fair value of stock options vested Net loss for the period Balances at June 30, 2020	45,268 12,000,000 - - - - -			-		86,739 27,119,880 1,407,501 695,454 50,741 273,462 257,482	- - - - (27,710,964)	86,740 27,120,000 1,407,501 695,454 50,741 273,462 257,482 (27,710,964)		86,740 27,120,000 1,407,501 695,454 50,741 273,462 257,482 (27,711,163)
settle accounts payable and accrued expenses Common stock issued to settle related party payables Common stock issued for asset purchase Paid-in capital - beneficial conversion feature Paid-in capital - fair value of stock warrants granted Paid-in capital - gain on related party payables conversion Paid-in capital - loss on extinguishment of convertible notes Paid-in capital - fair value of stock options vested Net loss for the period Balances at June 30, 2020 Paid-in capital - fair value of	45,268 12,000,000 - - - - -			-		86,739 27,119,880 1,407,501 695,454 50,741 273,462 257,482	- - - - (27,710,964)	86,740 27,120,000 1,407,501 695,454 50,741 273,462 257,482 (27,710,964)		86,740 27,120,000 1,407,501 695,454 50,741 273,462 257,482 (27,711,163)
settle accounts payable and accrued expenses Common stock issued to settle related party payables Common stock issued for asset purchase Paid-in capital - beneficial conversion feature Paid-in capital - fair value of stock warrants granted Paid-in capital - fair value of stock warrants granted Paid-in capital - loss on extinguishment of convertible notes Paid-in capital - fair value of stock options vested Net loss for the period Balances at June 30, 2020	45,268 12,000,000 - - - - -			-	- - - - - - - - - - - - - - - - - - -	86,739 27,119,880 1,407,501 695,454 50,741 273,462 257,482 \$48,203,770	- - - - (27,710,964)	86,740 27,120,000 1,407,501 695,454 50,741 273,462 257,482 (27,710,964) \$ 531,816 46,617	- - - - (199) \$(53,460)	86,740 27,120,000 1,407,501 695,454 50,741 273,462 257,482 (27,711,163) \$ 478,356
settle accounts payable and accrued expenses Common stock issued to settle related party payables Common stock issued for asset purchase Paid-in capital - beneficial conversion feature Paid-in capital - fair value of stock warrants granted Paid-in capital - fair value of stock warrants granted Paid-in capital - gain on related party payables conversion Paid-in capital - loss on extinguishment of convertible notes Paid-in capital - fair value of stock options vested Net loss for the period Balances at June 30, 2020	45,268 12,000,000 - - - - -			-	- - - - - - - - - - - - - - - - - - -	86,739 27,119,880 1,407,501 695,454 50,741 273,462 257,482 \$48,203,770	- - - - (27,710,964)	86,740 27,120,000 1,407,501 695,454 50,741 273,462 257,482 (27,710,964) \$ 531,816	- - - - (199) \$(53,460)	86,740 27,120,000 1,407,501 695,454 50,741 273,462 257,482 (27,711,163) \$ 478,356
settle accounts payable and accrued expenses Common stock issued to settle related party payables Common stock issued for asset purchase Paid-in capital - beneficial conversion feature Paid-in capital - fair value of stock warrants granted Paid-in capital - gain on related party payables conversion Paid-in capital - loss on extinguishment of convertible notes Paid-in capital - fair value of stock options vested Net loss for the period Balances at June 30, 2020 Paid-in capital - fair value of stock options vested Daid-in capital - fair value of stock options vested	45,268 12,000,000 - - - - -			-	- - - - - - - - - - - - - - - - - - -	86,739 27,119,880 1,407,501 695,454 50,741 273,462 257,482 \$48,203,770	- - - (27,710,964) \$(47,672,155)	86,740 27,120,000 1,407,501 695,454 50,741 273,462 257,482 (27,710,964) \$ 531,816 46,617	- - - - (199) \$(53,460)	86,740 27,120,000 1,407,501 695,454 50,741 273,462 257,482 (27,711,163) \$ 478,356 46,617
settle accounts payable and accrued expenses Common stock issued to settle related party payables Common stock issued for asset purchase Paid-in capital - beneficial conversion feature Paid-in capital - fair value of stock warrants granted Paid-in capital - gain on related party payables conversion Paid-in capital - loss on extinguishment of convertible notes Paid-in capital - fair value of stock options vested Net loss for the period Balances at June 30, 2020 Paid-in capital - fair value of stock options vested Dividends payable-Series A- I convertible preferred stock	45,268 12,000,000 - - - - -			-	- - - - - - - - - - - - - - - - - - -	86,739 27,119,880 1,407,501 695,454 50,741 273,462 257,482 \$48,203,770 46,617	- - - - - - - - - - - - - - - - - - -	86,740 27,120,000 1,407,501 695,454 50,741 273,462 257,482 (27,710,964) \$ 531,816 46,617 (161,880) (737,698)	- - - - - - - - - - - - - - - - - - -	86,740 27,120,000 1,407,501 695,454 50,741 273,462 257,482 (27,711,163) \$ 478,356 46,617 (161,880)

The accompanying notes are an integral part of the condensed consolidated financial statements.

SOBR Safe, Inc. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

	For The Nine M Septemb	
	2020	2019
Operating Activities:		
Net loss	\$ (28,898,637)	\$ (512,117
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	133,571	-
Loss on debt extinguishment, net	269,144	_
Change in fair value of derivative liability	(60,650)	(3,400
Amortization of interest - beneficial conversion feature	1,407,675	62,020
Stock warrants expense	8,656	36,103
Stock options expense	343,549	-
Stock-based compensation expense	41,302	-
Asset impairment adjustment Changes in assets and liabilities:	25,320,555	-
Prepaid expenses	994	3,591
Other assets	(8,680)	5,571
Accounts payable	140,906	(2,692
Accrued expenses	(83,495)	(1,393
Accrued interest payable	(6,697)	123,008
Related party payables	(51,976)	91,048
Stock subscriptions payable		1,303
Net cash used in operating activities	(1,443,783)	(202,529
inancing Activities:		
Proceeds from notes payable - related parties		116,625
Proceeds from notes payable - non-related parties	41,665	60,000
Proceeds from issuances of common stock - non-related parties	-	39,000
Proceeds from offering of preferred stock - related parties	1,700,000	
Net cash provided by financing activities	1,741,665	215,625
		10.000
Net Change In Cash	297,882	13,096
Cash At The Beginning Of The Period	681,759	89
Cash At The End Of The Period	<u>\$ 979,641</u>	\$ 13,185
Schedule Of Non-Cash Investing And Financing Activities:		
Gain on related party payables converted to capital	\$ 272,299	\$ 564,093
Accounts neurable and economical economicated to conital	\$ 265,677	\$ -
Accounts payable and accrued expenses converted to capital	\$ 203,077	<u> </u>
Related party payables converted to capital	<u>\$ 579,814</u>	\$ 59,500
Gain on related party conversion of preferred stock into common stock	<u>\$</u>	\$ 1,329,561
Related party debt converted to capital after exercise of cashless stock warrants	<u>\$ 65,728</u>	\$ -
Related party debt converted to capital	<u>\$ 826,964</u>	<u></u>
Non-related party debt converted to capital	\$ 166.526	¢
	\$ 166,526	<u>\$</u>
Jain on related party debt converted to capital	<u>\$ 124,291</u>	<u>\$</u>
hares issued for cash received in prior years	\$ 20,800	<u>\$</u>
air value of stock warrants granted	<u>\$</u>	\$ 54,535
air value of embedded conversion feature	<u>\$</u>	\$ 56,100
ssuance of common stock, stock warrants and convertible note for asset purchase	<u>\$ 29,222,955</u>	\$.
ntrinsic value-beneficial conversion feature	\$ 1,407,501	\$ -
xercise of cashless stock warrants	\$ -	\$ 146,774
referred stock dividend accrued	<u>\$</u> - <u>\$</u> 161,880	\$
Supplemental Disclosure:		
Cash paid for interest	<u>\$ 1,372</u>	\$ 3,750
		¢
Cash paid for income taxes	\$ -	\$ -

The accompanying notes are an integral part of the condensed consolidated financial statements.

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

TransBiotec, Inc. ("TransBiotec – DE"), formerly Imagine Media LTD., was incorporated August, 2007 in the State of Delaware. A corporation also named TransBiotec, Inc. ("TransBiotec – CA") was formed in the state of California July 4, 2004. Effective September 19, 2011 TransBiotec - DE was acquired by TransBiotec - CA in a transaction classified as a reverse acquisition as the shareholders of TransBiotec - CA retained the majority of the outstanding common stock of TransBiotec - DE after the share exchange. The financial statements represent the activity of TransBiotec - CA from July 4, 2004 forward, and the consolidated activity of TransBiotec - DE and TransBiotec - CA from September 19, 2011 forward. TransBiotec - DE and TransBiotec - CA are hereinafter referred to collectively as the "Company" or "We". The Company has developed and plans to market and sell a non-invasive alcohol sensing system which includes an ignition interlock. The Company has not generated any revenues from its operations.

On March 23, 2020, the Company filed a Definitive 14C providing notice that the Board of Directors has recommended, and that holders of a majority of the voting power of the Company's outstanding stock voted, to approve the following.

- 1. To remove and re-elect four (4) directors to serve until the next Annual Meeting of Shareholders and thereafter until their successors are elected and qualified; and
- 2. To approve an amendment to the Company's Certificate of Incorporation to: (a) change the Company's name to SOBR SAFE, Inc., (b) decrease the Company's authorized common stock from 800,000,000 shares, par value \$0.00001 to 100,000,000 shares, par value \$0.00001, and (c) effect a reverse stock split of the Company's outstanding common stock at a ratio between 1-for-32 and 1-for-35 (with the exact ratio to be determined by the directors in their sole discretion without further approval by the shareholders).

The above actions taken by the Company's stockholders became effective on or about May 21, 2020. The effective dates of the above actions were June 5, 2020 and April 20, 2020, respectively, and the actual reverse stock split ratio was 1-for-33.26. All share and per amounts have been adjusted in the financial statements to reflect the effect of the reverse stock split.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles ("GAAP") as promulgated in the United States of America and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). These unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and related notes for the year ended December 31, 2019, included in the Company's Annual Report on Form 10-K filed with the SEC on April 17, 2020.



In management's opinion, the unaudited condensed consolidated financial statements reflect all adjustments (including reclassifications and normal recurring adjustments) necessary to present fairly the financial position as of September 30, 2020 and December 31, 2019, and results of operations for the three month and nine month periods ended September 30, 2020 and 2019.

Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its majority owned subsidiary, TransBiotec-CA. We have eliminated all intercompany transactions and balances between entities consolidated in these unaudited condensed financial statements.

Use of Estimates

The preparation of unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Specifically, such estimates were made by the Company for the valuation of the derivative liabilities, beneficial conversion feature expenses and intellectual technology. Actual results could differ from those estimates.

Cash

The Company considers all highly liquid investments with an original maturity of three months or less as cash equivalents. The Company does not have any cash equivalents as of September 30, 2020 and December 31, 2019.

Financial Instruments

Pursuant to Accounting Standards Codification ("ASC") Topic 820, *Fair Value Measurements and Disclosures* and ASC 825, *Financial Instruments*, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 and 825 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 and 825 prioritizes the inputs into three levels that may be used to measure fair value:

Level 1

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets: quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The Company's financial instruments consist primarily of cash, accounts payable, accrued expenses, accrued interest payable, notes payable, related party payables, convertible debentures, and other payables. Pursuant to ASC 820 and 825, the fair value of our derivative liabilities is determined based on "Level 3" inputs. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.

The following table presents assets and liabilities that are measured and recognized at fair value as of September 30, 2020 and December 31, 2019:

September 30, 2020

	Level 1	Level 2	Level 3
Derivative liabilities	\$ -	\$ -	\$ -
	\$ -	\$ -	\$ -
December 31, 2019			
	Level 1	Level 2	Level 3
Derivative liabilities	<u>\$</u>	<u>\$</u> -	<u>\$ 60,650</u>
	\$ -	\$ -	\$ 60,650

Beneficial Conversion Features

From time to time, the Company may issue convertible notes that may contain a beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.

Derivative Instruments

The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instruments are initially recorded at their fair values and are then re-valued at each reporting date, with changes in the fair value reported in the unaudited condensed consolidated statements of operations under other income (expense). The accounting treatment of derivative financial instruments requires that the Company record the embedded conversion option at its fair value as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. As a result of entering into warrant agreements, for which such instruments contained a variable conversion feature with no floor, the Company has adopted a sequencing policy in accordance with ASC 815-40-35-12 whereby all future instruments may be classified as a derivative liability with the exception of instruments related to share-based compensation issued to employees or directors. For stock-based derivative financial instruments, the Company uses a Monte Carlo Simulation model to value the derivative instruments at inception and on subsequent valuation dates.



The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

Preferred Stock

We apply the guidance enumerated in ASC 480 "Distinguishing Liabilities from Equity" when determining the classification and measurement of preferred stock. Preferred shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. We classify conditionally redeemable preferred shares (if any), which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control, as temporary equity. At all other times, we classified our preferred shares in stockholders' equity.

Noncontrolling Interest

A subsidiary of the Company has minority members representing ownership interests of 1.38% at September 30, 2020 and December 31, 2019. The Company accounts for these minority, or noncontrolling interests, pursuant to ASC 810-10-65 whereby gains and losses in a subsidiary with a noncontrolling interest are allocated to the noncontrolling interest based on the ownership percentage of the noncontrolling interest, even if that allocation results in a deficit noncontrolling interest balance.

Stock-based Compensation

The Company follows the guidance of the accounting provisions of ASC 718 Share-based Compensation, which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (warrants and options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the future. Expected volatilities are based on weighted averages of the historical volatility of the Company's common stock estimated over the expected term of the options. The expected term of options granted is derived using the "simplified method" which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term.



Research and Development

The Company accounts for its research and development costs pursuant to ASC 730, whereby it requires the Company to disclose the amounts of costs for company and customer-sponsored research and development activities, if material. Research and development costs are expensed as incurred. The Company incurred research and development costs as it acquired new knowledge to bring about significant improvements in the functionality and design of its SOBR product. Research and development costs were \$309,403 and none during the nine month periods ended September 30, 2020 and 2019, respectively.

Income Tax

The Company accounts for income taxes pursuant to Accounting Standards Codification ASC 740. Under ASC 740 deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company has not recorded any deferred tax assets or liabilities at September 30, 2020 and December 31, 2019, respectively.

Loss Per Share

Basic loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the periods. Diluted loss per share give the effect to all dilutive potential common shares outstanding during the periods including stock options, warrants and convertible instruments. Diluted loss per share exclude all potentially issuable shares if their effect is anti-dilutive. Because the effect of the Company's dilutive securities is anti-dilutive, diluted loss per share is the same as basic loss per share for the periods presented.

Related Parties

Related parties are any entities or individuals that, through employment, ownership or other means, possess the ability to direct or cause the direction of the management and policies of the Company.

New Pronouncements

In December 2019, the FASB issued ASU No. 2019-12, *Simplifying the Accounting for Income Taxes* ("ASU 2019-12"), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, *Income Taxes*, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The Company is evaluating the effects, if any, of the adoption of ASU 2019-12 guidance on the Company's financial position, results of operations and cash flows.

In August 2020, the FASB issued ASU No. 2020-06, *Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity,* which address issues identified as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. This amendment is effective for public business entities that meet the definition of a SEC filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is evaluating the effects, if any, of the adoption of ASU 2020-06 guidance on the Company's financial position, results of operations and cash flows.

In October 2020, the FASB issued ASU No. 2020-08, *Codification Improvements to Subtopic 310-20, Receivables-Nonrefundable Fees and Other Costs,* amendments the guidance in ASU No. 2017-08, (Subtopic 310-20): *Premium Amortization on Purchased Callable Debt Securities*, which addresses multiple call dates of a callable debt security. This amendment is effective for public business entities, for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Early application is not permitted. The Company is evaluating the effects, if any, of the adoption of ASU 2020-08 guidance on the Company's financial position, results of operations and cash flows.

NOTE 2. GOING CONCERN

The Company has suffered recurring losses from operations and has a working capital deficit and stockholders' deficit, and in all likelihood, will be required to make significant future expenditures in connection with continuing marketing efforts along with general and administrative expenses. As of September 30, 2020, the Company has an accumulated deficit of approximately \$48,570,000. During the nine months ended September 30, 2020, the Company also experienced negative cash flows from operating activities of \$1,443,783. It appears these principal conditions or events, considered in the aggregate, indicate it is probable that the entity will be unable to meet its obligations as they become due within one year after the date the financial statements are issued. As such, there is substantial doubt about the entity's ability to continue as a going concern.

The Company has been considering opportunities to create synergy with its SOBR product to mitigate the probable conditions that have raised substantial doubt about the entity's ability to continue as a going concern.

On May 6, 2019, the Company entered into an Asset Purchase Agreement with IDTEC, LLC (and Amendment No. 1 dated March 9, 2020) (the "APA"), under which IDTEC, LLC ("IDTEC"), an affiliate owned by First Capital Holdings, LLC ("FCH"), agreed to provide personnel, experience, and access to funding to assist with the development of the Company's SOBR device, as well as to sell to the Company certain robotics assets, which the Company's management believes are synergistic with its current assets. The APA transaction closed on June 5, 2020 providing the Company with ownership in the SOBR Safe intellectual technology.

On December 12, 2019, the Company entered into a Series A-1 Preferred Stock Purchase Agreement (the "SPA") with SOBR SAFE, LLC ("SOBR SAFE"), a Delaware limited liability company and an entity controlled by Gary Graham, one of the Company's Directors, under which (i) the Company agreed to create a new series of convertible preferred stock entitled "Series A-1 Convertible Preferred Stock," with 2,000,000 shares authorized and the following rights: (a) dividend rights of 8% per annum based on the original issuance price of \$1 per share, (b) liquidation preference over our common stock, (c) conversion rights into shares of our common stock at \$1 per share, (d) redemption rights such that the Company has the right, upon thirty days written notice, at any time after one year from the date of issuance, to redeem all or part of the Series A-1 Convertible Preferred Stock for 150% of the original issuance price, (e) shall not be callable by the Company, and (f) each share of Series A-1 Convertible Preferred Stock will vote on an "as converted" basis; and (ii) SOBR SAFE agreed to acquire 1,000,000 shares of the Company's Series A-1 Convertible Preferred Stock (the "Preferred Shares"), once created, in exchange for \$1,000,000 (the "Purchase Price"). The Company received the Purchase Price on December 12, 2019 and has not issued these Preferred Shares as of September 30, 2020: however, the Company plans to issue these Preferred Shares in the fourth quarter of 2020. On May 7, 2020, the Company amended a Convertible Preferred Stock Investment Agreement granting the exclusive right to SOBR SAFE to purchase up to 2,700,000 shares. The Company has a cash balance of \$979,641 and \$681,759 at September 30, 2020 and December 31, 2019, respectively.

On January 30, 2020, the World Health Organization ("WHO") announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the "COVID-19 outbreak") and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve as of the date of this Annual Report. Management is actively monitoring the global situation on its financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for fiscal year 2020. However, if the pandemic continues, it will have an adverse effect on the Company's results of future operations, financial position, and liquidity in year 2020.

Management believes actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern; however, these plans are contingent upon actions to be performed by the Company and these conditions have not been met on or before September 30, 2020. Additionally, the COVID-19 outbreak could have a continued adverse impact on economic and market conditions and trigger a period of global economic slowdown, which would impair the Company's ability to raise needed funds to continue as a going concern. As such, substantial doubt about the entity's ability to continue as a going concern was not alleviated as of September 30, 2020.

NOTE 3. ASSET PURCHASE

On June 5, 2020, the Company completed a transaction (the "Transaction") with IDTEC subject to the terms and conditions of the APA and that was accounted for as an asset purchase. Pursuant to the APA, IDTEC provided personnel, experience, and access to funding to assist with the development of the SOBR device, as well as sold to us certain robotics assets, which our management believes are synergistic with our current assets, in exchange for 12,000,000 shares of our common stock after giving effect to the reverse stock split effected in connection with closing the Transaction. The closing of the Transaction was subject to several conditions precedent, primarily: (i) the Company had to be current in reporting requirements under the Securities Exchange Act of 1934, as amended, (ii) had to complete a reverse stock split of common stock such that approximately 8,000,000 shares were outstanding immediately prior to closing the transaction, (iii) could only have outstanding convertible instruments as set forth in the APA, (iv) authorized common stock had to be reduced to 100,000,000 shares, and (v) not have more than approximately \$125,000 in current liabilities. Effective with the closing of the Transaction all of the closing conditions had been met, modified or waived by IDTEC, and the Company issued the 12,000,000 shares to IDTEC.

In advance of closing the Transaction, IDTEC and a few other affiliated parties voluntarily committed personnel and funds to the Company to assist with (i) general costs related to the Transaction, (ii) ongoing operating expenses and pay for further engineering and development work on the Company's products and prototypes, (iii) protect, maintain and develop the Company's products and intellectual property, (iv) hire, pay and retain the proposed management team, third party consultants and advisors for the Company's products and intellectual property, (iv) hire, pay and retain the proposed management team, third party consultants and advisors for the Company's business subsequent to the sale contemplated in the APA and, (v) take such further actions as are necessary to more quickly expand the Company's business subsequent to the sale of the purchased assets. The parties agreed that the funds advanced directly to the Company's vendors were voluntary and were not the obligation of the Company and the Company had no obligation to repay these funds in the event the transaction contemplated by the APA did not close. In the event the Transaction did close, then on the closing date, the Company would issue promissory notes for the aggregate amounts incurred, paid or advanced. As a result of closing the Transaction, the Company issued a convertible promissory note for all the funds spent or advanced by IDTEC prior to closing. This note totaled \$1,485,189 (the "APA Note"), with simple interest at 10% per annum, due upon demand, and may be convertible into shares of common stock at \$0.50 per share (after giving effect to the reverse stock split and subject to anti-dilution protection against any future securities we may issue at an effective price of less than \$0.50 per share) at the discretion of the holder. The repayment of APA Note is secured by a first priority security lien or security interest in the patents, trademarks, trademarks, and other intellectual property of the Company.

At closing, some of the closing conditions under the APA were either waived and/or modified by the parties. In order to document those modifications and waivers, we entered into a Waiver Under Asset Purchase Agreement and Post-Closing Covenant Agreement with IDTEC. One of the closing conditions that was the subject of the Waiver Under Asset Purchase Agreement and Post-Closing Covenant Agreement was the requirement that the Company have under \$125,000 in permitted liabilities (not including aged liabilities) after closing of the Transaction. At closing we had approximately \$158,000 in non-permitted liabilities under the APA. As a result, the Company issued a Warrant to Purchase Common Stock to IDTEC (the "Warrant"), under which IDTEC will purchase up to 320,000 shares of our common stock (post-split) at an exercise price of \$0.50 per share, if either (i) we are forced to pay a non-permitted liability, then we may force IDTEC to exercise the Warrant and pay the exercise price to pay the non-permitted liability, or (ii) if IDTEC otherwise elects to exercise the Warrant and acquire some or all of the shares underlying the Warrant. The Warrant expires five years after the date of issuance.

The Transaction recorded as an asset purchase was valued at \$29,222,955, which consists of the market price as of June 5, 2020 of the Company's 12,000,000 shares of common stock issued totaling \$27,120,000, the funds spent by IDTEC and affiliates prior to closing of \$1,407,051 and the fair value of the Warrant issued of \$695,454.

The following summarizes the transaction closing with IDTEC on June 5, 2020:

Property and equipment	\$ 47,725
Intangible assets	 29,175,230
Total assets	\$ 29,222,955
Net purchase (fair value of stock issued, warrants and funds spent)	\$ 29,222,955

Subsequent to the Transaction closing, the Company evaluated the fair value of the assets acquired based on market estimates for property and equipment and discounted net cash flow for the SOBR Safe intellectual technology. The present value of the discounted cash flow utilized a 75% discount, which included a 25% risk return premium, over an estimated five-year net revenue stream expected to be derived from the technology acquired. Based on the assessment of fair value, the Company recognized an asset impairment loss of \$25,320,555 resulting from the APA during the three-month period ended June 30, 2020. The impairment was due to the increase of the Company's stock price value. The stock price of the Company at closing of the Transaction was significantly higher than expected from the stock price of the Company signed the APA. The number of shares to be given to IDTEC as consideration for the Transaction would not get updated for any stock price changes.

In determining the fair value of the intangible assets, the Company considered, among other factors, the best use of acquired assets such as the analysis of historical financial performance of the products and estimates of future performance of the products and intellectual properties acquired. The preliminary establishment of the allocation to identifiable intangible assets required extensive use of financial information and management's best estimate of fair value. The Company has preliminarily recorded the purchase price of the identified intangible assets and is, if applicable, amortizing such assets over their estimated useful lives of ten years. The assessment of fair value is preliminary and is based on information that was available to management at the time the unaudited condensed consolidated financial statements were prepared. Measurement period adjustments will be recorded in the period in which they are determined, as if they had been completed at the acquisition date. Accordingly, differences between these preliminary estimates and the final allocation to the intangible assets may occur and these differences could have a material impact on the accompanying consolidated financial statements.

NOTE 4. PROPERTY AND EQUIPMENT

Property and equipment, net consists of the following:

	Se	eptember 30, 2020
Robotics and testing equipment	\$	46,200
Office furniture and equipment		1,525
		47,725
Accumulated depreciation		(5,083)
Property and equipment, net	\$	42,642

Depreciation is computed on a straight-line basis over the assets estimated useful lives of three years. Depreciation for the three and nine months ended September 30, 2020 was \$3,978 and \$5,083, respectively . There was no depreciation for the three and nine months ended September 30, 2019.

NOTE 5. INTANGIBLE ASSETS

Intangible assets consist of the following at September 30, 2020:

	Gross Carrying Amount	mulated	I	Net ntangible Asset	Amortization Period (in vears)
SOBR Safe	 			110500	(
Intellectual Technology	\$ 3,854,675	\$ 128,488	\$	3,726,187	10

Amortization expense for the three and nine months ended September 30, 2020 was \$96,366 and \$128,488, respectively. There was no amortization expense for the three and nine months ended September 30, 2019.

Estimated future amortization expense for device technology intangible assets is as follows:

2021		20	22	2023	2024	2025	1	Thereafter
	85,467	\$	385,467	\$ 385,467	\$ 385,467	\$ 385,467	\$	1,798,852

NOTE 6. RELATED PARTY TRANSACTIONS

On December 3, 2014, Lanphere Law Group, a related party and the Company's largest shareholder, entered into an agreement with the Company to convert 50% of its outstanding accounts payable of \$428,668 to a note payable. This note payable represents one half of the balance in the amount of \$214,334 of legal fees and costs owed up until October 31, 2014. This agreement further provided that the remaining 50% of unpaid legal fees in accounts payable were to be paid and retained as a current payable. In addition, 50% of the legal fees and costs incurred beginning with the legal services provided to the Company on November 1, 2014 are to be converted on a monthly basis to common stock at a price of \$0.09 per share until the accounts payable balance for legal fees is paid current. The Company has recorded to equity, a total related party gain connected to these conversions during the nine month period ended September 30, 2020 and 2019 of none and \$22,585, respectively. The Company converted the remaining payables to common stock through a separate agreement and there are no more payables to convert as of September 30, 2020.

On July 1, 2015, the Company amended the December 3, 2014 note payable agreement with Lanphere Law Group, a related party and the Company's largest shareholder, which forgave \$108,000 of the note payable's principal balance. This debt forgiveness decreased the original principal balance on the note of \$214,334 to a new principal balance of \$106,335, and a related party gain of \$108,000 was recorded to additional paid-in capital. This amendment also extended the note payable's due date to December 2, 2015. The note was converted to common stock during the three months ended March 31, 2020.

On March 8, 2017, Lanphere Law Group, a related party and the Company's largest shareholder, irrevocably elected to exercise warrants in order to acquire 969,601 shares of the Company's common stock in exchange for an aggregate exercise price of \$112,871, which was used for the deduction of \$74,672 of principal and \$38,199 of accrued interest related to the December 3, 2014 note payable agreement with Lanphere Law Group. The forgiveness of the note payable principal of \$74,672 was recorded to equity and the \$38,199 of related accrued interest was also recorded to equity. The principal balance of the note after the debt deduction was \$31,662. On January 3, 2020, the note payable principal balance of \$31,662 was converted to 9,520 common shares at a per share price of \$3.326. As of September 30, 2020 and December 31, 2019, the principal balance of this note was none and \$31,662, respectively. As of September 30, 2020 and December 31, 2019, the accrued interest on this note was none and \$9,508, respectively.

Due to cash flow constraints, the Company experienced difficulty in compensating its directors for their service in their capacity as directors; therefore, such directors may receive stock options to purchase common shares as awarded by its Board of Directors or (as to future stock options) a compensation committee which may be established. Directors are entitled to reimbursement for reasonable travel and other out-of-pocket expenses incurred in connection with business related travel and attendance at meetings of its Board of Directors. The Company's Board of Directors may award special remuneration to any director undertaking any special services on our behalf other than services ordinarily required of a director. On August 23, 2019, the Company entered into a Common Stock Purchase Agreement (the "Bennington SPA") with Charles Bennington, one of the Company's officers and directors, under which the Company agreed to issue 420,926 shares of its common stock in exchange for Mr. Bennington forgiving \$595,000 in accrued compensation and services due. The Company also recorded a related party gain on the conversion of executive compensation to common shares of \$353,500 that was accounted for as additional paid-in capital. The common shares were issued on or about August 28, 2019 at a per-share purchase price of \$1.4135 per share.

On August 23, 2019, the Company entered into a Debt Conversion and Common Stock Purchase Plan (the "Lanphere SPA") with Michael Lanphere, one of the Company's officers, under which the Company agreed to issue 643,438 shares of its common stock in exchange for a reduction in the amounts owed to Mr. Lanphere under numerous promissory notes. Mr. Lanphere's option to acquire the shares was under the terms of certain Loan Agreement with Promissory Note and Stock Fees agreements entered into with the Company and Mr. Lanphere. The amount of the debt reduction and, therefore the purchase price of the shares, was \$96,303 which was used for the deduction of related party notes payable principal of \$77,927 and accrued interest of \$18,376. The Company recognized a related party gain of \$5,350 and accounted for it as additional paid-in capital. The common shares were issued on or about August 28, 2019 at an effective conversion price of \$0.1497 per share. After this exercise, Lanphere Law Group owned warrants to acquire an additional 454,097 shares of our common stock, which were subsequently exercised during 2020.

On August 23, 2019, the Company entered into a Debt Conversion and Common Stock Purchase Plan (the "Mishal SPA") with Devadatt Mishal, one of the Company's directors, under which the Company agreed to issue 394,901 shares of its common stock in exchange for a reduction in the amounts owed to Mr. Mishal under numerous promissory notes. Mr. Mishal's option to acquire the shares was under the terms of certain Loan Agreement with Promissory Note and Stock Fees agreements entered into with the Company and Mr. Mishal. The amount of the debt reduction and, therefore the purchase price of the shares, was \$56,478 which was used for the deduction of related party notes payable principal of \$45,000 and accrued interest of \$11,478. The Company recognized a related party gain of \$657 and accounted for it as additional paid-in capital. The common shares were issued on or about August 28, 2019 at an effective conversion price of \$0.1430 per share. After this exercise, Devadatt Mishal owns no warrants to acquire additional shares of our common stock.

On August 23, 2019, the Company entered into a Share Exchange Agreement (the "Lanphere SEA") with Michael Lanphere, one of the Company's officers, under which the Company agreed to issue 156,537 shares of its common stock in exchange for 520,643 shares of the Company's Series A Convertible Preferred Stock owned by Mr. Lanphere. The Series A Convertible Preferred stock were exchanged for the Company's common shares at a price of \$3.326 per share. The fair value of the common shares was \$22,127. Per ASC 470-50-40-2, debt modification and extinguishment transactions between related parties are in essence a capital contribution from a related party. As a result, rather than recording a gain on extinguishment of debt, the Company recorded \$498,516 to additional paid-in capital.

On August 23, 2019, the Company entered into a Share Exchange Agreement (the "Justus SEA") with Vernon Justus, a related party, under which the Company agreed to issue 260,954 shares of its common stock in exchange for 867,932 shares of the Company's Series A Convertible Preferred Stock owned by Mr. Justus. The Series A Convertible Preferred stock were exchanged for the Company's common shares at a price of \$3.326 per share. The fair value of the common shares was \$36,887. Per ASC 470-50-40-2, debt modification and extinguishment transactions between related parties are in essence a capital contribution from a related party. As a result, rather than recording a gain on extinguishment of debt, the Company recorded \$831,045 to additional paid-in capital.

The Company entered into a lease agreement with Lanphere Law Group, a related party, whereas the Company was the tenant and paying monthly rent of \$4,100. The term of this operating lease ran from July 1, 2015 to June 30, 2019. From July 1, 2019 through December 31, 2019, the Company leased the same office space on a month to month basis. Rent expense, including CAM charges, for the nine month period ended September 30, 2020 and 2019 of none and \$39,315, respectively, was accounted for as general and administrative expense.

On January 3, 2020, the Company entered into a Debt Conversion and Common Stock Purchase Plan with Michael Lanphere, one of the Company's officers, under which he agreed to exercise and the Company agreed to issue 454,097 shares of its common stock in exchange for a reduction in the amounts owed to Mr. Lanphere under two promissory notes. Mr. Lanphere's option to acquire the shares was under the terms of certain Loan Agreement with Promissory Note and Stock Fees agreements entered into with the Company and Mr. Lanphere on April 17, 2019 and July 17, 2019. The amount of the debt reduction, and therefore the purchase price of the shares, was \$65,875 which was used for the deduction of related party notes payable principal of \$65,875. 180,397 common shares were issued on January 3, 2020 at an effective conversion price of \$0.133 and 273,700 common shares were issued on January 3, 2020 at an effective conversion price of \$0.153. After this exercise, Lanphere Law Group owns no warrants for shares of our common stock.

On January 3, 2020, the Company entered into another Debt Conversion and Common Stock Purchase Plan with Michael Lanphere, one of the Company's officers, under which the Company agreed to issue 63,225 shares of its common stock in exchange for a reduction in the amounts owed to Mr. Lanphere under numerous other remaining promissory notes. The amount of the debt reduction, and therefore the purchase price of the shares, was \$210,285 which was used for the deduction of related party notes payable principal of \$169,606 and accrued interest of \$40,679. Based on the fair value of the shares issued, the Company recognized a related party gain of approximately \$52,000 and accounted for it as additional paid-in capital. The common shares were issued on January 3, 2020 at an effective conversion price of \$3.326 per share.

On January 3, 2020, the Company entered into a Debt Conversion and Common Stock Purchase Plan with Vernon Justus, a related party, under which the Company agreed to issue 84,963 shares of its common stock in exchange for a reduction in the amounts owed to Mr. Justus under a promissory note. The amount of the debt reduction, and therefore the purchase price of the shares, was \$282,588 which was used for the deduction of a related party note payable principal of \$180,001 and accrued interest of \$102,587. Based on the fair value of the shares issued, the Company recognized a related party gain of approximately \$70,000 and accounted for it as additional paid-in capital. The common shares were issued on January 3, 2020 at an effective conversion price of \$3.326 per share.

On January 16, 2020, the Company entered into a Accounts Payable Conversion and Common Stock Purchase Plan with Michael Lanphere, one of the Company's officers, under which the Company agreed to issue 214,883 shares of its common stock in exchange for a reduction in the amounts owed to Mr. Lanphere for unpaid legal bills. The amount of the debt reduction, and therefore the purchase price of the shares, was \$714,700 which was used for the deduction of related party payables of \$714,700. Based on the fair value of the shares issued, the Company recognized a related party gain of approximately \$222,000 and accounted for it as additional paid-in capital. The common shares were issued on January 16, 2020 at an effective conversion price of \$3.326 per share.

On January 30, 2020, the Company entered into a Debt Conversion and Common Stock Purchase Plan with Devadatt Mishal, one of the Company's directors, under which the Company agreed to issue 499,965 shares of its common stock in exchange for a reduction in the amounts owed to Mr. Mishal under numerous promissory notes. The amount of the debt reduction, and therefore the purchase price of the shares, was \$456,641 which was used for the deduction of related party notes payable principal of \$270,300 and accrued interest of \$186,500. The Company also recorded a loss on related party debt extinguishment of approximately \$144,000. The common shares were issued on January 30, 2020 at an effective conversion price of \$0.91465 per share.

On March 23, 2020, the Company entered into a Debt Conversion and Common Stock Purchase Plan with Prakash Gadgil, one of the Company's former directors, under which the Company agreed to issue 586 shares of its common stock in exchange for a reduction in the amounts owed to Mr. Gadgil under a promissory note. The amount of the debt reduction, and therefore the purchase price of the shares, was \$1,950 which was used for the deduction of a related party note payable principal of \$1,950. Based on the fair value of the shares issued, the Company recognized a related party gain of approximately \$1,000 and accounted for it as additional paid-in capital. The common shares were issued on March 23, 2020 at an effective conversion price of \$3.326 per share.

On April 6, 2020, the Company agreed with Nick Noceti, the Company's former Chief Financial Officer, to issue 38,437 shares of its common stock in exchange for amounts due for accounting fees included in accounts payable. The amount of the debt reduction, and therefore the purchase price of the shares, was \$127,840 which was used for the deduction of a related party accounts payable of \$127,480. Based on the fair value of the shares issued, the Company recognized a related party gain of approximately \$49,000 and accounted for it as additional paid-in capital. The common shares were issued on April 4, 2020 at an effective conversion price of \$3.326 per share.

On April 7, 2020, the Company agreed with Charles Bennington, one of the Company's former directors, to issue 6,831 shares of its common stock in exchange for amounts due for Board of Director fees included in accounts payable. The amount of the debt reduction, and therefore the purchase price of the shares, was \$9,656 which was used for the deduction of a related party accounts payable of \$9,656. Based on the fair value of the shares issued, the Company recognized a related party gain of approximately \$2,000 and accounted for it as additional paid-in capital. The common shares were issued on April 7, 2020 at an effective conversion price of \$1.41 per share.

NOTE 7. NOTES PAYABLE

Related Parties

The Company has convertible notes payable to related parties that have a principal balance of \$1,485,189 and \$161,000 as of September 30, 2020 and December 31, 2019, respectively. The principal balance consists of one 10% convertible note payable due on demand. The notes carry fixed and variable conversion prices per share. The Company evaluated these convertible notes payable for derivative embedded conversion features and beneficial conversion features. The Company determined that there were both derivative embedded conversion features and beneficial conversion features to record. The conversion features were either fully amortized upon grant or over the life of the convertible notes payable. The conversion features were fully amortized as of September 30, 2020 and December 31, 2019. During the nine months ended September 30, 2020 and 2019, beneficial conversion feature amortization expense related to these convertible notes payable of \$1,407,675 and none, respectively, was accounted for as amortization of interest - beneficial conversion feature amortization expense related to these consolidated statements of operations. During the nine months ended March 31, 2020, the Company entered into a Debt Conversion and Common Stock Purchase Plan with a related party, under which the Company agreed to issue 156,474 shares of its common stock in exchange for a reduction of four convertible notes payable to related party, convertible notes payable principal of \$91,000 and accrued interest of \$52,119.

The Company has a non-convertible notes payable to related parties principal balance of \$11,810 and \$328,423 as of September 30, 2020 and December 31, 2019, respectively. The principal balance consists of one zero interest note payable with a due date of December 31, 2012. This note is currently in default. During the three months ended March 31, 2020, the Company converted eight non-convertible notes payable to related parties that had a principal balance of \$316,613. During the three months ended March 31, 2020, the Company entered into Debt Conversion and Common Stock Purchase Plans with four related parties, under which the Company agreed to issue 342,399 shares of its common stock in exchange for a reduction of eight non-convertible notes payable to related parties. The amount of the debt reduction, and therefore the purchase price of the shares, was \$549,311 which was used for the deduction of related party non-convertible notes payable principal of \$316,613 and accrued interest of \$232,698.

The Company has a notes payable with detached free-standing warrants to related parties principal balance of none and \$280,119 as of September 30, 2020 and December 31, 2019, respectively. These notes carried interest rates ranging from 7% - 10% and had due dates ranging from 08/05/2015 - 03/30/2020. The exercise price for each note payable with detached free-standing warrants ranged from \$0.03 - \$0.53. As of September 30, 2020 and December 31, 2019, these notes carried outstanding detached free-standing warrants of none and 454,097, respectively. The unamortized discount at September 30, 2020 and December 31, 2019 is none and \$8,656, respectively. During the nine-month period ended September 30, 2020 and 2019, stock warrants amortization expense recorded as interest expense was \$8,656 and \$36,103, respectively. The relative fair market value of the related stock warrants granted during the nine-month period ended September 30, 2020 and 2019, stock warrants granted during the nine-month period ended September 30, 2020 and 2019 was none and \$54,535, respectively. During the three months ended March 31, 2020, the Company entered into Debt Conversion and Common Stock Purchase Plans with two related parties, under which the Company agreed to issue 601,783 shares of its common stock in exchange for a reduction of 24 notes payable with detached free-standing warrants to related party notes payable with detached free-standing warrants principal of \$280,119 and accrued interest of \$40,739.

Total interest expense for related party notes was \$79,596 and \$65,919 for the nine-month period ended September 30, 2020 and 2019, respectively.

Related party notes payable consist of the following:

	Sej	ptember 30, 2020	De	cember31, 2019
Convertible Notes Payable	\$	1,485,189	\$	161,000
Conventional Non-Convertible Notes Payable		11,810		328,423
Notes Payable with Detached Free-standing Warrants		-		280,119
Unamortized Discount		-		(8,656)
Net Related Party Notes Payable	\$	1,496,999	\$	760,886

Non-Related Parties

The Company has convertible notes payable to non-related parties that have a principal balance of \$56,683 and \$143,136 as of September 30, 2020 and December 31, 2019, respectively. These notes carry interest rates ranging from 5% - 12% and have due dates ranging from 2/20/2013 - 3/06/2022. Two of the three notes are currently in default. These notes carry conversion prices ranging from \$1.99 - \$10.76 per share. The Company evaluated these convertible notes payable for derivative embedded conversion features and beneficial conversion features. The Company determined that there were beneficial conversion features to record. The conversion features were either fully amortized upon grant or over the life of the convertible notes payable. The conversion features were fully amortized as of September 30, 2020 and December 31, 2019. During the nine months ended September 30, 2020 and 2019, beneficial conversion feature amortization expense related to these convertible notes payable of none and \$5,920, respectively, was accounted for as amortization of interest - beneficial conversion feature expense in the condensed consolidated statements of operations. During the three month period ended March 31, 2020, the Company entered into Debt Conversion and Common Stock Purchase Plans with six non-related parties, under which the Company agreed to issue 50,135 shares of its common stock in exchange for a reduction of eleven convertible notes payable to non-related parties. The amount of the debt reduction, and therefore the purchase price of the shares, was \$166,749 which was used for the deduction of non-related party convertible notes payable principal of \$83,952 and accrued interest of \$82,797. The Company recorded a non-related party gain on loan extinguishment of approximately \$68,000. During the three months ended March 31, 2020, the Company also entered into a non-related party convertible note payable agreement to convert a high interest rate convertible non-related party note payable with a principal balance of \$25,000 and accrued interest due of \$22,500 to a non-related party convertible note payable of \$47,500 that accrues interest at 5%. The note conversion rate is \$2 per common share. The Company recorded a loss on non-related party debt extinguishment of \$11,697. On June 9, 2020, the holder of a \$25,000 convertible promissory note with interest at 30% and accrued interest of \$61,875 replaced the carrying amount of the note and its conversion features with a new non-convertible note totaling \$47,500 that bears interest at 5%. The Company recorded a gain on non-related party debt extinguishment of \$61,875.

The Company has non-convertible notes payable to non-related parties that have a principal balance of \$84,165 and \$21,438 as of September 30, 2020 and December 31, 2019, respectively. These notes carry interest rates ranging from 1% - 10% and have due dates ranging from 12/27/2013 - 6/6/2022. Two of the four notes are currently in default. During the three month period ended March 31, 2020, the Company entered into a Debt Conversion and Common Stock Purchase Plan with a non-related party, under which the Company agreed to issue 20,313 shares of its common stock in exchange for a reduction of his non-convertible non-related party note payable. The amount of the debt reduction, and therefore the purchase price of the shares, was \$67,561 which was used for the deduction of non-related party non-convertible notes payable principal of \$3,938 and accrued interest of \$63,623. The Company recorded a non-related party gain on loan extinguishment of \$39,000. On May 12, 2020, the Company received proceeds of \$41,665 from a commercial bank under the SBA Payroll Protection Loan Program. The loan requires interest at 1% and 18 monthly payments of principal and interest beginning December 5, 2020. Provisions of the SBA Payroll Protection Loan Program allow for portions or all the loan balance to be forgiven should certain criteria be met. The Company expects that it will meet the criteria for the full of amount of loan forgiveness.

The Company has one note payable with detached free-standing warrants to a non-related party that has a principal balance of \$5,000 as of September 30, 2020 and December 31, 2019. This note carries an interest rate of 10% and had a due date of 9/11/2014. This note is currently in default. The detached free-standing warrants for this note payable were not exercised by the note holder and expired on May 16, 2019.

Total interest expense for non-related party notes was \$14,036 and \$44,643 for the nine-month period ended September 30, 2020 and 2019, respectively.

Non- related party notes payable consist of the following:

	ember 30, 2020	Dec	ember 31, 2019
Convertible Notes Payable	\$ 56,683	\$	143,136
Conventional Non-Convertible Notes Payable	84,165		21,438
Notes Payable with Detached Free-standing Warrants	 5,000		5,000
Net Non-Related Party Notes Payable	\$ 145,848	\$	169,574

NOTE 8. DERIVATIVE LIABILITY

In 2019, the Company borrowed \$ 70,000 under convertible promissory notes agreement from an unrelated party that are due upon demand. The notes bear interest at a rate of 10% per annum and are convertible into the Company's common shares at a variable conversion price based on a 50% discount of the market price at an undetermined future date. The Company analyzed the conversion features of the note agreement for derivative accounting consideration under ASU 2017-11 (ASC 815-15 Derivatives and Hedging), and determined the embedded conversion features should be classified as a derivative because the exercise price of the convertible note is subject to a variable conversion rate and should therefore be accounted for at fair value under ASC 820, *Fair Value Measurements and Disclosures, and ASC 825, Financial Instruments*. In accordance with ASC 815-15, the Company has bifurcated the conversion feature of the note and recorded a derivative liability.

The embedded derivative for the notes were carried on the Company's balance sheet at fair value. The derivative liability is marked to market each measurement period and any unrealized change in fair value is recorded as a component of the statement of operations and the associated fair value carrying amount on the balance sheet is adjusted by the change. The Company fair values the embedded derivatives using a Monte Carlo simulation model based on the following assumptions: (1) expected volatility of 180%, (2) risk-free interest rate of 0.13%, and (3) expected life from 1 month to 1 year. On March 1, 2019, the date of the first note, the fair value of the embedded derivative was \$28,000. On May 3, 2019, the date of the second note, the fair value of the embedded derivative was \$28,000. On May 3, 2019, the date of the second note, the fair value of the embedded derivative was \$28,000. On May 3, 2019, the date of the second note, the fair value of the embedded derivative was \$28,000. On May 3, 2019, the date of the second note, the fair value of the embedded derivative was \$28,000. On October 26, 2019, the date of the third note, the fair value of the embedded derivative was \$8,700. The notes carried an embedded conversion feature of \$64,800 that was fully amortized to interest expense during the year ended December 31, 2019. The notes were not converted and deemed paid in full at the closing of the Transaction on June 5, 2020. The principal amounts of these notes were settled and transferred to the APA Note and a loss on debt extinguishment of \$273,462 was recognized during the nine-month period ended September 30, 2020. The fair value of the embedded derivative recorded on the balance sheet as a liability was none and \$60,650 at September 30, 2020 and December 31, 2019, respectively. Utilizing level 3 inputs, the Company recorded a fair market value gain of \$60,650 during the nine months ended September 30, 2020 and a gain of \$3,400 during same period ended September 30, 2019.

A summary of the activity of the derivative liability is shown below:

Balance at December 31, 2019	\$ 60,650
Fair market value adjustments (including settlements)	 (60, 650)
Balance at September 30, 2020	\$ 0

NOTE 9. STOCK SUBSCRIPTIONS PAYABLE

The Company has common stock subscriptions payable due to related parties of \$79,624 payable with 89,077 of its common shares at September 30, 2020 and December 31, 2019. The Company recorded a related party gain of none and \$22,585 related to the outstanding common stock subscriptions payable during the nine month period ended September 30, 2020 and 2019, respectively.

The Company has common stock subscriptions payable due to non-related parties of \$20,504 payable with 15,108 of its common shares at September 30, 2020. The Company had no common stock subscriptions payable due to non-related parties at December 31, 2019.

The Company has preferred stock subscriptions payable due to related parties of \$2,700,000 payable with 2,700,000 of its 8% Series A-1 Convertible Preferred shares as of September 30, 2020. The Company has preferred stock subscriptions payable due to related parties of \$1,000,000 payable with 1,000,000 of its 8% Series A-1 Convertible Preferred shares as of December 31, 2019.

NOTE 10. COMMON STOCK

On February 25, 2019, the Company issued 1,065,982 shares of its common stock to non-related parties for \$39,000 in cash.

On August 23, 2019, the Company converted \$56,478 of related party debt into 394,901 shares of its common stock at \$0.1430 per share.

On August 23, 2019, the Company converted \$96,303 of related party debt into 643,438 shares of its common stock at \$0.1497 per share.

On August 23, 2019, the Company converted \$595,000 of accrued executive compensation owed to a related party into 420,926 shares of its common stock at \$3.326 per share.

On August 23, 2019, the Company issued to a related party 156,537 shares of its common stock in exchange for 520,643 shares of the Company's Series A Convertible Preferred Stock at \$3.326 per share. The fair value of the common shares was \$22,127. Per ASC 470-50-40-2, debt modification and extinguishment transactions between related parties are in essence a capital contribution from a related party. As a result, rather than recording a gain on extinguishment of debt, the Company recorded \$498,516 to additional paid-in capital on the unaudited condensed consolidated balance sheet.

On August 23, 2019, the Company issued to a related party 260,954 shares of its common stock in exchange for 867,932 shares of the Company's Series A Convertible Preferred Stock at \$3.326 per share. Per ASC 470-50-40-2, debt modification and extinguishment transactions between related parties are in essence a capital contribution from a related party. As a result, rather than recording a gain on extinguishment of debt, the Company recorded \$831,045 to additional paid-in capital on the unaudited condensed consolidated balance sheet.

On January 3, 2020, the Company converted \$34,534 of non-related party debt into 10,383 issued shares of its common stock at \$3.326 per share and recorded a non-related party gain of \$6,907 as other income in the consolidated statements of operations.

On January 3, 2020, the Company converted \$6,482 of non-related party debt into 1,949 issued shares of its common stock at \$3.326 per share and recorded a non-related party gain of \$1,296 as other income in the consolidated statements of operations.

On January 3, 2020, the Company converted \$39,356 of non-related party debt into 11,833 issued shares of its common stock at \$3.326 per share and recorded a non-related party gain of \$7,871 as other income in the consolidated statements of operations.

On January 3, 2020, the Company converted \$97,624 of non-related party debt into 29,352 issued shares of its common stock at \$3.326 per share and recorded a non-related party gain of \$19,525 as other income in the consolidated statements of operations.

SOBR Safe, Inc.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2020

On January 3, 2020, a related party exercised 273,700 stock warrants and in exchange converted \$41,875 in related party debt owed to him under a promissory note. The shares were issued at a value of \$0.1530 per share pursuant to the terms of the convertible note.

On January 3, 2020, a related party exercised 180,397 stock warrants and in exchange converted \$24,000 in related party debt owed to him under a promissory note. The shares were issued at a value of \$0.13304 per share pursuant to the terms of the convertible note.

On January 3, 2020, the Company converted \$210,285 of related party debt into 63,225 issued shares of its common stock at \$3.326 per share and recorded a related party gain of \$42,057 to additional paid-in capital.

On January 3, 2020, the Company converted \$282,588 of related party debt into 84,963 issued shares of its common stock at \$3.326 per share and recorded a related party gain of \$56,518 to additional paid-in capital.

On January 16, 2020, the Company converted \$40,000 of non-related party accounts payable into 12,026 issued shares of its common stock at \$3.326 per share and recorded a non-related party gain of \$22,840 as other income in the consolidated statements of operations.

On January 16, 2020, the Company converted \$87,464 of non-related party accounts payable into 26,297 issued shares of its common stock at \$3.326 per share and recorded a non-related party gain of \$49,942 as other income in the consolidated statements of operations.

On January 16, 2020, the Company converted \$714,700 of related party payables into 214,883 issued shares of its common stock at \$3.326 per share and recorded a related party gain of \$408,094 to additional paid-in capital.

On January 22, 2020, the Company converted \$23,814 of non-related party debt into 7,160 issued shares of its common stock at \$3.326 per share and recorded a non-related party gain of \$14,289 as other income in the consolidated statements of operations.

On January 30, 2020, the Company converted \$456,641 of related party debt into 499,965 issued shares of its common stock at \$0.9146 per share and recorded a related party gain of \$456,634 to additional paid-in capital. The Company recorded a loss on debt extinguishment of \$143,660 as other expense in the consolidated statements of operations.

On March 15, 2020, the Company converted \$32,500 of non-related party debt into 9,771 issued shares of its common stock at \$3.326 per share and recorded a non-related party gain of \$19,240 as other income in the consolidated statements of operations.

On March 20, 2020, the Company issued 601 common shares at \$34.59 per share to a non-related party as stock compensation for services provided.

On March 23, 2020, the Company converted \$1,950 of related party debt into 586 issued shares of its common stock at \$3.326 per share and recorded a related party gain of \$1,073 to additional paid-in capital.

On April 1, 2020, the Company converted \$43,750 of non-related party debt into 75,165 issued shares of its common stock at \$0.5821 per share and recorded a non-related party loss of \$43,743 as other expense in the consolidated statements of operations. On April 6, 2020, the Company issued 38,437 shares of its common stock to a related party in exchange for their agreement to settle a related party accounts payable of \$127,840 owed to them. The shares were issued at a value of \$79,133 and recorded a related party gain of \$48,707 to additional paid-in-capital.

On April 7, 2020, the Company issued 6,831 shares of its common stock to a related party in exchange for their agreement to settle an accounts payable balance of \$9,656 owed to them. The shares were issued at a value of \$7,621 and recorded a related party gain of \$2,035 to additional paid-in-capital.

On April 20, 2020, the Company agreed to convert 9,346 shares of its common stock at \$1.039 per share to a non-related party in exchange for their agreement to settle a payable balance of \$9,714 owed to them. The conversion was in full satisfaction of all outstanding amounts owed. The Company recorded a non-related party loss of \$854 as other expense in the consolidated statements of operations.

On April 21, 2020, the Company agreed to convert 36,560 shares of its common stock at \$1.039 per share to a non-related party in exchange for their agreement to settle a payable balance of \$38,000 owed to them. The conversion was in full satisfaction of all outstanding amounts owed. The Company recorded a non-related party loss of \$37,270 as other expense in the consolidated statements of operations.

NOTE 11. PREFERRED STOCK

On November 20, 2015, the Company's Board of Directors authorized a class of stock designated as preferred stock with a par value of \$0.00001 per share comprising 25,000,000 shares, 3,000,000 shares of which were classified as Series A Convertible Preferred Stock. In each calendar year, the holders of the Series A Convertible Preferred Stock are entitled to receive, when, as and if, declared by the Board of Directors, out of any funds and assets of the Company legally available, non-cumulative dividends, in an amount equal to any dividends or other Distribution on the common stock in such calendar year (other than a Common Stock Dividend). No dividends (other than a Common Stock Dividend) shall be paid and no distribution shall be made with respect to the common stock unless dividends shall have been paid or declared and set apart for payment to the holders of the Series A Convertible Preferred Stock simultaneously. Dividends on the Series A Convertible Preferred Stock shall not be mandatory or cumulative, and no rights or interest shall accrue to the holders of the Series A Convertible Preferred Stock by reason of the fact that the Company shall fail to declare or pay dividends on the Series A Convertible Preferred Stock, except for such rights or interest that may arise as a result of the Company paying a dividend or making a distribution on the common stock in violation of the terms. The holders of each share of Series A Convertible Preferred Stock then outstanding shall be entitled to be paid, out of the Available Funds and Assets, and prior and in preference to any payment or Distribution (or any setting part of any payment or Distribution) of any Available Funds and Assets on any shares of common stock, and equal in preference to any payment or Distribution (or any setting part of any payment or Distribution) of any Available Funds and Assets on any shares of any other series of preferred stock that have liquidation preference, an amount per share equal to the Original Issue Price of the Series A Convertible Preferred Stock plus all declared but unpaid dividends on the Series A Convertible Preferred Stock. A reorganization, or any other consolidation or merger of the Company with or into any other corporation, or any other sale of all or substantially all of the assets of the Company, shall not be deemed a liquidation, dissolution, or winding up of the Company. Shares of the Series A Convertible Preferred Stock are convertible at a 35% discount rate to the average closing price per share of the Company's common stock (either as listed on a national exchange or as quoted over-the-market) for the last 15 trading days immediately prior to conversion. However, no conversions of the Series A Convertible Preferred Stock to shares of common stock can occur unless the average closing price per share of the Corporation's common stock (either as listed on a national exchange or as quoted over-the-market) for the last 15 trading days immediately prior to conversion is at least \$1.67. The shares of Series A Convertible Preferred Stock vote on a one for one basis. The right of conversion is limited by the fact the holder of the Series A Convertible Preferred Stock may not convert if such conversion would cause the holder to beneficially own more than 4.9% of the Company's common stock after giving effect to such conversion.



On August 8, 2019, the Company entered into an 8% Series A-1 Convertible Preferred Stock Investment Agreement (the "Investment Agreement") with First Capital Ventures, LLC ("FCV"), and its assignee. The Company desires to raise between \$1,000,000 and \$2,000,000 from the sale of its 8% Series A-1 Convertible Preferred Stock and FCV intends to raise between \$1,000,000 and \$2,000,000 (net after offering expenses) in a special purchase vehicle ("SPV") created by FCV to purchase the 8% Series A-1 Convertible Preferred Stock. The Company granted FCV and its assigns, the exclusive right to purchase the 8% Series A-1 Convertible Preferred Stock. The Company granted FCV and its assigns, the exclusive right to purchase the 8% Series A-1 Convertible Preferred Stock. The Company granted FCV at three-year stock warrant to purchase the 8% Series A-1 Convertible Preferred Stock. The Company further agreed to issue FCV a three-year stock warrant to purchase 144,317 shares of its common stock at an exercise price of \$1.039375 per share immediately following the closing date, which was valued at \$122,889 and expensed upon grant for services provided. The Company agreed to enter into a "business development" agreement with FCV, or its assignee, on the sale of the first \$1,000,000 of 8% Series A-1 Convertible Preferred Stock and also granted FCV and its assigns, the right to use the name "SOBR SAFE" and any related intellectual property in connection with the SPV, and the offering of the Interests in the SPV.

In accordance with the August 8, 2019 Investment Agreement with FCV, on December 9, 2019, the Company's Board of Directors created a class of preferred stock designated as 8% Series A-1 Convertible Preferred Stock comprising of 2,000,000 shares. The rights and preferences of the 8% Series A-1 Convertible Preferred Stock are as follows: (a) dividend rights of 8% per annum based on the original issuance price of \$1 per share, (b) liquidation preference over the Company's common stock, (c) conversion rights into shares of the Company's common stock at \$1 per share (not to be affected by any reverse stock split in connection with the Asset Purchase Agreement with IDTEC), (d) redemption rights such that we have the right, upon 30 days written notice, at any time after one year from the date of issuance, to redeem all or part of the Series A-1 Convertible Preferred Stock for 150% of the original issuance price, (e) no call rights by the Company, and (f) each share of Series A-1 Convertible Preferred Stock will vote on an "as converted" basis.

On August 23, 2019, the Company entered into a Share Exchange Agreement (the "Lanphere" SEA) with Michael Lanphere, one of the Company's officers, under which the Company agreed to issue 156,537 shares of its common stock in exchange for 520,643 shares of the Company's Series A Convertible Preferred Stock owned by Mr. Lanphere. The Series A Convertible Preferred stock were exchanged for the Company's common shares at a price of \$3.326 per share and were issued on or about August 28, 2019. The fair value of the common shares was \$22,127. Per ASC 470-50-40-2, debt modification and extinguishment transactions between related parties are in essence a capital contribution from a related party. As a result, rather than recording a gain on extinguishment of debt, the Company recorded \$498,516 to additional paid-in capital on the unaudited condensed consolidated balance sheet.

On August 23, 2019, the Company entered into a Share Exchange Agreement (the "Justus" SEA) with Vernon Justus, an individual, under which the Company agreed to issue 260,954 shares of its common stock in exchange for 867,932 shares of the Company's Series A Convertible Preferred Stock owned by Mr. Justus. The Series A Convertible Preferred stock were exchanged for the Company's common shares at a price of \$3.326 per share and were issued on or about August 28, 2019. The fair value of the common shares was \$36,887. Per ASC 470-50-40-2, debt modification and extinguishment transactions between related parties are in essence a capital contribution from a related party. As a result, rather than recording a gain on extinguishment of debt, the Company recorded \$831,045 to additional paid-in capital on the unaudited condensed consolidated balance sheet.

On December 12, 2019, the Company entered into a Series A-1 Preferred Stock Purchase Agreement (the "SPA") with SOBR SAFE, LLC ("SOBR SAFE"), a Delaware limited liability company and an entity controlled by Gary Graham, one of our Directors, under which SOBR SAFE agreed to acquire 1,000,000 shares of our Series A-1 Convertible Preferred Stock (the "Preferred Shares"), in exchange for \$1,000,000 (the "Purchase Price"). The Company received the Purchase Price on December 12, 2019. In connection with the closing of the SPA, holders of the Company's common stock representing approximately 52% of the Company's then-outstanding common stock and voting rights signed irrevocable proxies to Gary Graham and/or Mr. Spieker to vote those shares on any matters necessary to close the transaction that is the subject of the certain Asset Purchase Agreement with IDTEC dated May 6, 2019, as amended.

SOBR Safe, Inc.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2020

On May 7, 2020, the Company amended a Convertible Preferred Stock Investment Agreement granting the exclusive right to SOBR SAFE to purchase up to 2,700,000 shares.

As of September 30, 2020 and December 31, 2019, the Company has sold 2,700,000 and 1,000,000 shares of its 8% Series A-1 Convertible Preferred Stock, respectively, but has not issued any stock certificates yet.

On July 2, 2020, the Company executed Amendment No. 2 to the Convertible Preferred Stock Investment Agreement which provides that the full amount of each dividend due on a dividend payment date, even if not declared, shall be paid to any holder regardless of the date on which the holder acquired the stock.

The Series A-1 Convertible Preferred Stock earns cumulative dividends at a rate of 8% per annum, payable in cash or common stock at the option of the Company on June 30 and December 31 of each year. If paid in common stock, the common stock will be valued at the average of the closing price for the five business days prior to the dividend payment date. The preferred shareholders will participate in any common stock dividends on an as converted basis. Although no dividends were declared as of September 30, 2020 and 2019, the Company has accrued dividends payable of \$161,880 related to the 8% Series A-1 Convertible Preferred Stock as of September 30, 2020.

NOTE 12. STOCK WARRANTS AND STOCK OPTIONS

Stock Warrants

The Company accounts for employee stock options and non-employee stock warrants under ASC 718 and ASC 505, whereby option costs are recorded based on the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable, utilizing the Black Sholes pricing model. Unless otherwise provided for, the Company covers option exercises by issuing new shares.

Beginning on December 12, 2012, Michael A. Lanphere, a related party and non-employee, loaned the Company money for a variety of purposes, some for working capital and some to allow the Company to pay outstanding obligations. Each of these loans were made pursuant to the terms of a Loan Agreement with Promissory Note and Stock Fee (the "Agreements"). Under the terms of the Agreements, Mr. Laphere was not only entitled to repayment of the principal amount loaned to us, with interest, but also what was termed in the Agreements as a "Stock Fee" that the parties are interpreting as a stock warrant, which permits Mr. Lanphere to acquire shares of our common stock in exchange for an exercise price that was estimated based on the date of the loan agreement. The number of shares to be issued to Mr. Lanphere as a Stock Fee under each Agreement was an estimate and varied based on the loan amount and the price of our common stock on the day of the loan and was calculated by this formula: 60% or 80% of the loan amount divided by the Company's stock price on the day of the loan, but at a price per share no higher than \$0.025. Each Stock Fee is fully vested immediately and expires 5 years from the date of the loan. Although the Stock Fee could be taken by Mr. Lanphere as a stock grant or a stock warrant, due to the fully vested nature of the Stock Fee, Mr. Lanphere is deemed to beneficially own those shares on the date of each Agreement. After the Company entered into a Debt Conversion and Common Stock Purchase Plan with Mr. Lanphere dated January 3, 2020, Mr. Lanphere agreed to exercise his stock warrants and the Company agreed to convert and issue 454,097 shares of its common stock to reduce a notes payable principal balance consisting of two notes in the amount of \$65,875. The Company did not record a loss on debt extinguishment for this conversion pursuant to ASC 470-20-40-4 that states that upon conversion in accordance with its original terms, the carrying amount of the convertible debt without a BCF, including any unamortized premium or discount, is credited to the capital accounts and no gain or loss should be recognized. Mr. Lanphere owns no more warrants to shares of our common stock. The number of warrants outstanding to Mr. Lanphere at September 30, 2020 and December 31, 2019 were none and 454,097, respectively.



On August 8, 2019, the Company entered into an 8% Series A-1 Convertible Preferred Stock Investment agreement with First Capital Ventures, LLC ("FCV"). FCV set up a special purpose vehicle ("SPV") that purchased 1,000,000 of the 8% Series A-1 Convertible Preferred Shares at \$1.00 per share on December 12, 2019. Upon purchase, the Company issued the SPV through FCV a three-year warrant to purchase 144,317 shares of the Company's common stock at an exercise price of \$1.039375 per share. The number of warrants outstanding to the SPV through FCV at September 30, 2020 and December 31, 2019 are 144,317 and 144,317, respectively.

On June 5, 2020, at closing of the Transaction, the Company entered into a Waiver Under Asset Purchase Agreement and Post-Closing Covenant Agreement under which we issued warrants to IDTEC to purchase up to 320,000 shares of our common stock (post-split) at an exercise price of \$0.50 per share. The warrants expire five years after the date of issuance.

The total outstanding balance of all non-employee stock warrants in the Company is 464,317 and 598,414 at September 30, 2020 and December 31 2019, respectively. There were 320,000 non-employee detached free-standing stock warrants granted during the nine month period ended September 30, 2020 and 772,261 non-employee detached free-standing stock warrants granted during the nine month period ended September 30, 2019. The relative fair value of these non-employee stock warrants granted during the nine month period ended September 30, 2019 totaled \$695,454 and \$54,535, respectively, and were determined using the Black-Sholes option pricing model based on the following assumptions:

	Sept. 30, 2020	Sept. 30, 2019
Exercise Price	\$ 0.50	\$ 0.06 - 0.2
Dividend Yield	0%	0%
Volatility	153%	134% - 138%
Risk-free Interest Rate	0.29%	1.83% - 2.53%
Life of Warrants	5 Years	5 Years

The following table summarizes the changes in the Company's outstanding warrants during the nine month period ended September 30, 2020 and 2019, and as of September 30, 2020 and 2019:

		Weighted			
Warrants		Average	Weighted		
Outstanding	Exercise Price	Remaining	Average	Α	ggregate
Number of	Per	Contractual	Exercise Price]	ntrinsic
Shares	Share	Life	Per Share		Value
721,678	\$0.1397 - 0.6319	3.45 Years	\$ 0.1929	\$	-
772,261	\$0.06 - 0.2062	4.50 Years	\$ 0.1231	\$	161,129
(1,038,339)	\$0.06 - 0.5322		\$ 0.1630		
(1,503)	\$ 0.6319		\$ 0.6319		
454,097	\$.1330 - 0.1530	4.55 Years	\$ 0.1463	\$	85,158
	Outstanding Number of Shares 721,678 772,261 (1,038,339) (1,503)	Outstanding Number of Shares Exercise Price Per 721,678 \$0.1397 - 0.6319 772,261 \$0.06 - 0.2062 (1,038,339) \$0.06 - 0.5322 (1,503) \$0.6319	Warrants Average Outstanding Exercise Price Remaining Number of Per Contractual Shares Share Life 721,678 \$0.1397 - 0.6319 3.45 Years 772,261 \$0.06 - 0.2062 4.50 Years (1,038,339) \$0.06 - 0.5322	Warrants Outstanding Number of Shares Exercise Price Per Shares Average Remaining Share Weighted Average 721,678 \$0.1397 - 0.6319 3.45 Years \$0.1929 772,261 \$0.06 - 0.2062 4.50 Years \$0.1231 (1,038,339) \$0.06 - 0.5322 \$0.6319 \$0.6319 (1,503) \$0.0619 \$0.0619 \$0.6319	Warrants Outstanding Number of Shares Exercise Price Per Average Remaining Contractual Weighted Average A 5 Shares Share Contractual Exercise Price I 721,678 \$0.1397 - 0.6319 3.45 Years \$0.1929 \$ 772,261 \$0.06 - 0.2062 4.50 Years \$0.1231 \$ (1,038,339) \$0.06 - 0.5322 \$0.6319 \$ 0.6319

*** * * * *

	Warrants Outstanding Number of Shares	Exercise Price Per Share	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Balance at December 31, 2019	598,414	\$0.13304 - 1.039375	3.97 Years	\$ 0.3607	\$ 1,276,870
Warrants Granted	320,000	\$ 0.50	4.68 Years	\$ 0.50	\$ 761,600
Warrants Exercised	(454,097)	\$ 0.13304 - 0.15299		\$ 0.1451	
Warrants Expired	-				
Balance at September 30, 2020	464,317	\$0.50 - 1.039375	3.91 Years	\$ 0.66765	\$ 1,027,234
Exercisable at December 31, 2019	598,414	\$0.13304 - 1.039375	3.97 Years	\$ 0.3607	\$ 1,276,870
Exercisable at September 30, 2020	464,317	\$0.50 - 1.039375	3.91 Years	\$ 0.66765	\$ 1,027,234

Stock Options

On October 24, 2019, the Company's 2019 Equity Incentive Plan went effective. The plan was approved by the Company's Board of Directors and the holders of a majority of the Company's voting stock on September 9, 2019. The plan's number of authorized shares is 3,848,467. As of September 30, 2020 and December 31, 2019, the Company granted stock options to acquire 2,541,239 and 2,381,239 shares of common stock under the plan, respectively. As of September 30, 2020, the plan has 1,213,060 vested shares and 1,328,179 non-vested shares. As of December 31, 2019, the plan had 539,847 vested shares and 1,841,392 non-vested shares. The stock options are held by our officers, directors, employees, and certain key consultants. In total for the nine months ended September 30, 2020 and 2019, the Company recorded \$343,549 and none, respectively, of share-based compensation expense related to the stock options. The unrecognized compensation expense as of September 30, 2020 was approximately \$358,000 for non-vested shares and share-based awards to be recognized over periods of approximately three to seven years.

In applying the Black-Scholes options-pricing model, assumptions used to compute the fair value of the stock options granted during the nine month period ended September 30, 2020 and 2019 were as follows:

	September 30, 2020	September 30, 2019
Exercise Price	\$0.26-	
	3.30	-
Dividend Yield	0%	-
Expected Volatility	153%-	
	171%	-
Risk Free Interest Rate	0.19%-	
	0.43%	-
Expected Life	2.2-5	
	years	-

The following table summarizes the changes in the Company's outstanding stock options during the nine month period ended September 30, 2020 and 2019, and as of September 30, 2020 and 2019.

	Options Outstanding Number of Shares	Exercise Price Per Share	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Balance at December 31, 2018	53,367	0.1497 - 8.31	2.32 Years	\$ 0.2761	\$ -
Options Granted	-	-			
Options Exercised	-	-			
Options Cancelled	(45,100)	\$ 0.1497		\$ 0.1497	
Options Expired	-	-			
Balance at September 30, 2019	8,267	\$0.2328 - 8.31	0.07 Years	\$ 0.9678	\$-

	Options Outstanding Number of Shares	Exercise Price Per Share	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value
Balance at December 31, 2019	2,381,239	\$0.2634 - 1.039	8.86 Years	\$ 0.2946	\$ 5,238,080
Options Granted	160,000	0.2634 - 3.30	4.10 Years	\$ 1.9454	\$ 149,532
Options Exercised	-	-			
Options Cancelled	-	-			
Options Expired	-	-			
Balance at September 30, 2020	2,541,239	\$0.26342 - 3.30	7.86 Years	\$ 0.3987	\$ 6,305,579
Exercisable at December 31, 2019	539,847	\$0.2634 - 1.03938	8.93 Years	\$ 0.4	\$ 1,129,786
Exercisable at September 30, 2020	1,213,060	\$0.26342 - 3.30	8.21 Years	\$ 0.5009	\$ 2,885,963

Executive Stock Options

The Company has 829,492 outstanding executive stock options exercisable at \$0.2634 per share as of September 30, 2020 and 299,317 outstanding executive stock options as of December 31, 2019.

On October 25, 2019, the Company granted Charles Bennington, one of the Company's directors, options to acquire 24,053 shares of the Company's common stock under its 2019 Equity Incentive Plan. The stock options have an exercise price of \$0.2634 and vest quarterly over a one-year period commencing January 1, 2020. The stock options have a five-year term. A total of 18,040 and 0 stock options were vested as of September 30, 2020 and December 31, 2019, respectively. None of the vested stock options have been exercised and no shares have been issued as of September 30, 2020.

On October 25, 2019, the Company granted Nick Noceti, the former Company's Chief Financial Officer, options to acquire 24,053 shares of the Company's common stock under its 2019 Equity Incentive Plan. The stock options have an exercise price of \$0.2634 and vest quarterly over a two-year period commencing January 1, 2020. The stock options have a five-year term. A total of 9,020 and 0 stock options were vested as of September 30, 2020 and December 31, 2019, respectively. None of the vested stock options have been exercised and no shares have been issued as of September 30, 2020.

On October 25, 2019, the Company granted Gary Graham, one of the Company's directors, options to acquire 24,053 shares of the Company's common stock under its 2019 Equity Incentive Plan. The stock options have an exercise price of \$0.2634 and vest quarterly over a one-year period commencing January 1, 2020. The stock options have a five-year term. A total of 18,040 and 0 stock options were vested as of September 30, 2020 and December 31, 2019, respectively. None of the vested stock options have been exercised and no shares have been issued as of September 30, 2020.

On October 25, 2019, the Company entered into an Employment Agreement with Kevin Moore to serve as the Company's Chief Executive Officer. Under the terms of the agreement, the Company granted Kevin Moore stock options under its 2019 Equity Compensation Plan to acquire 1,058,328 shares of its common stock at an exercise price of \$0.2634. The stock options vest in 36 equal monthly installments of 29,398 shares during the three-year term of his Employment Agreement. A total of 323,378 and 58,796 stock options were vested as of September 30, 2020 and December 31, 2019, respectively. None of the vested stock options have been exercised and no shares have been issued as of September 30, 2020 or December 31, 2019.

On October 25, 2019, the Company entered into an Employment Agreement with David Gandini to serve as the Company's Chief Revenue Officer. Under the terms of the agreement, the Company granted David Gandini stock options under its 2019 Equity Compensation Plan to acquire 721,588 shares of its common stock at an exercise price of \$0.2634. The stock options vest in 36 equal monthly installments of 20,044 shares during the three-year term of his Employment Agreement. David Gandini was also granted an aggregate of 240,529 additional option shares (the "Pre-Vesting Option Shares") to vest as follows: (i) 200,439 Pre-Vesting Option Shares representing the monthly vesting option shares for the ten months ended October 31, 2019 to vest on November 1, 2019; and (ii) the remaining 40,090 Pre-Vesting Option Shares representing the monthly vesting option shares for the two months ended December 31, 2019 shall vest on January 1, 2020. The stock options have a ten-year term. A total of 461,014 and 240,521 stock options were vested as of September 30, 2020 and December 31, 2019, respectively. None of the vested stock options have been exercised and no shares have been issued as of September 30, 2020 or December 31, 2019.

NOTE 13. COMMITMENTS AND CONTINGENCIES

Operating Leases

The Company leased office space under a long-term operating lease that expired in June 2019. The Company leased the same office space on a month to month basis until December 31, 2019. On October 15, 2019, the Company entered into a short-term lease agreement with Highland School that is between \$2,800 - \$2,900 per month and ends on October 31, 2020. The lease has been renewed for another twelve months under the same general terms and conditions. The Company also leases an office space for \$1,300 per month on a short-term (month to month) basis through a related party that terminates at any time. Rent expense under office leases, including CAM charges, was \$47,711 and \$39,315 for the nine month period ended September 30, 2020 and 2019, respectively.

Legal Proceedings

On December 6, 2006, Orange County Valet and Security Patrol, Inc. filed a lawsuit against us in Orange County California State Superior Court for Breach of Contract in the amount of \$11,164. A default judgment was taken against us in this matter. In mid-2013 we learned the Plaintiff's perfected the judgment against us, but we have not heard from the Plaintiffs as of November 2020.

We currently have one outstanding judgment against us involving a past employee of the Company. The matter is under the purview of the State of California, Franchise Tax Board, Industrial Health and Safety Collections. We currently owe approximately \$28,786, plus accrued interest, to our exemployee for unpaid wages under these Orders and we are working to get this amount paid off.

NOTE 14. SUBSEQUENT EVENTS

The Company has evaluated subsequent events for recognition and disclosure through November 16, 2020, which is the date the condensed consolidated financial statements were available to be issued, and has determined that there are no other material subsequent events that require recognition or disclosure in the accompanying condensed consolidated financial statements.



ITEM 2 Management's Discussion and Analysis of Financial Condition and Results of Operations

Disclaimer Regarding Forward Looking Statements

Our Management's Discussion and Analysis or Plan of Operations contains not only statements that are historical facts, but also statements that are forward-looking. Forward-looking statements are, by their very nature, uncertain and risky. These risks and uncertainties include international, national and local general economic and market conditions; demographic changes; our ability to sustain, manage, or forecast growth; our ability to successfully make and integrate acquisitions; raw material costs and availability; new product development and introduction; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; the loss of significant customers or suppliers; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to arttract and retain qualified personnel; the ability to protect technology; and other risks that might be detailed from time to time in our filings with the Securities and Exchange Commission ("SEC").

Although the forward-looking statements in this Quarterly Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by them. Consequently, and because forward-looking statements are inherently subject to risks and uncertainties, the actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in this report and in our other reports as we attempt to advise interested parties of the risks and factors that may affect our business, financial condition, and results of operations and prospects.

Reverse Stock Split

At the open of market on June 8, 2020, our 1-for-33.26 reverse split of our common stock went effective with OTC Markets. As a result, all common stock share amounts, as well as share amounts and exercise and conversion prices in derivative security instruments have been adjusted to reflect the reverse stock split.

Overview

We intend to create substance-free environments by integrating and commercializing critical detection technologies. Our mission is to save lives, increase productivity, create significant economic benefit and positively impact behavior. To that end, we developed the patented SOBR® SafeTM system for non-invasive alcohol detection and identity verification, a solution that has anticipated applications in school buses, commercial vehicle fleets and facility access control, as well as addiction treatment and managed care.

The SOBR® SafeTM system can be deployed across numerous platforms for various uses, the first platform is our centralized access control product SOBR®CheckTM. When installed in manufacturing facilities, warehouses and more, SOBR®CheckTM enables a rapid, hygienic finger scan, with real-time results, delivered securely to the employer for any necessary corrective action. Currently, additional platforms for our alcohol detection system also include an app-based wearable band for ongoing monitoring, and integrations with current law enforcement technologies to enhance public safety. In addition, we are proactively evaluating other emerging detection technologies for alcohol, cannabis, opioids, heart rate and more.

Finally, we believe are platform portfolio approach could yield a highly valuable information asset. The opportunity to collect hundreds of thousands of data points over time could enable the development of predictive analytics for perpetual safety improvement (and associated cost savings capture). And by demonstrating substance-free environments, employers could deliver a data-driven argument for lowering insurance premiums.

As noted above, for our initial platform for our SOBR® SafeTM system we have developed and patented a touch-based identity verification and alcohol detection system called SOBR®CheckTM. SOBR®CheckTM is a potentially disruptive technology with anticipated applications in 1) commercial fleet management, 2) school buses, 3) manufacturing facilities and 4) warehousing. We have begun our initial pilot testing, which will continue through the end of 2020 with the goal to finalize the commercial product design and manufacturing strategy by that time. We anticipate beginning commercialization in the first quarter of 2021. SOBR®CheckTM will be manufactured in the United States.

We have developed a marketing plan that includes 1) multi-channel investor relations, 2) popular and trade media public relations, 3) advocacy group alignment, 4) video-centric social media outreach, 5) deploying savvy business development partners specific to and expert in the market segments/applications defined above 6) and continual research around the potential integration of detection technology for THC and opiates, to name a few.

In addition to focusing on the development, marketing, and commercialization of the SOBR®CheckTM device, we are also constantly reviewing potential synergistic technologies and businesses for potential partnerships or as acquisition candidates.

On June 5, 2020, we closed the transaction (the "Transaction") that was the subject of that certain Asset Purchase Agreement dated May 6, 2019 (and Amendment No. 1 dated March 9, 2020, together the "APA") with IDTEC, LLC ("IDTEC"), under which IDTEC agreed to provide personnel, experience, and access to funding to assist with the development of our SOBR device, as well as to sell to us certain robotics assets, which our management believes are synergistic with our current assets, in exchange for 12,000,000 shares of our common stock after giving effect to the reverse stock split effected in connection with closing the transaction. The closing of the Transaction was subject to several conditions precedent, primarily: (i) we had to be current in our reporting requirements under the Securities Exchange Act of 1934, as amended, (ii) we had to complete a reverse stock split of our common stock such that approximately 8,000,000 shares were outstanding immediately prior to closing the transaction, (iii) we could only have outstanding convertible instruments as set forth in the APA, (iv) our authorized common stock had to be reduced to 100,000,000 shares, and (v) we could not have more than approximately \$125,000 in current liabilities. Effective with the closing of the transaction all of the closing conditions had been met, modified or waived by IDTEC, and we issued the 12,000,000 shares to IDTEC in exchange for IDTEC providing access to personnel, experience, funding to assist with the development of our SOBR device, as well as the robotics assets. The description of the APA set forth in this report is qualified in its entirety by reference to the full text of that document and the amendment, which are attached hereto as Exhibits 10.1 and 10.12, respectively.

In advance of closing the Transaction, IDTEC and a few other affiliated parties (i) loaned funds directly to us, (ii) spent funds for the general costs related to the Transaction, and/or (iii) spent funds to further develop and enhance the current SOBR product. As a result of closing the Transaction, all the funds spent by IDTEC for any reason related to the Transaction were turned into a convertible promissory note. This note totaled approximately \$1,485,000 at closing, carries a simple interest rate of 10% per annum, is due upon demand, and may be convertible into shares of our common stock at \$0.50 per share (after giving effect to the reverse stock split and subject to anti-dilution protection against any future securities we may issue at an effective price of less than \$0.50 per share) at the discretion of the holder. The repayment of this promissory note is secured by a first priority security lien or security interest in our patents, trademarks, trademarks and other intellectual property described in Exhibit A of the promissory note. The convertible promissory note we issued is in the form attached hereto as Exhibit 10.13.

At closing, some of the closing conditions under the APA were either waived and/or modified by the parties. In order to document those modifications and waivers, we entered into a Waiver Under Asset Purchase Agreement and Post-Closing Covenant Agreement with IDTEC. One of the closing conditions that was the subject of the Waiver Under Asset Purchase Agreement and Post-Closing Covenant Agreement was the requirement that the Company have under \$125,000 in permitted liabilities (not including aged liabilities) after closing of the Transaction. At closing we had approximately \$158,000 in non-permitted liabilities under the APA. As a result, the Company issued a Warrant to Purchase Common Stock to IDTEC (the "Warrant"), under which IDTEC will purchase up to 320,000 shares of our common stock (post-split) at an exercise price of \$0.50 per share, if either (i) we are forced to pay a non-permitted liability, the non-permitted liability, or (ii) if IDTEC otherwise elects to exercise the Warrant and acquire some or all of the shares underlying the Warrant. The Warrant expires five years after the date of issuance.

Corporate Overview

We were formed in August 2007 to publish and distribute Image Magazine, a monthly guide and entertainment source for the Denver, Colorado area. We generated only limited revenue and essentially abandoned the business plan in January 2009. On September 19, 2011, we, Imagine Media, Ltd., a Delaware corporation, acquired approximately 52% of the outstanding shares of TransBiotec, Inc. (the "Company" or "TBT"), a California corporation, from TBT's directors in exchange for 373,315 shares of our common stock.

On January 17, 2012, our Board of Directors amended our Certificate of Incorporation changing our name from Imagine Media, Ltd. to TransBiotec, Inc.

On January 31, 2012, we acquired approximately 45% of the remaining outstanding shares of TBT in exchange for 329,936 shares of our common stock.

With the acquisitions in September 2011 and January 2012 of TBT common stock, we own approximately 99% of the outstanding shares of TBT.

As a result of the acquisitions, TBT's business is our business, and, unless otherwise indicated, any references to "we" or "us" include the business and operations of TBT.

On March 9, 2020, our Board of Directors approved the amendment to our Certificate of Incorporation on March 9, 2020 and stockholders holding 52.24% of our then outstanding voting stock approved the amendment to our Articles of Incorporation. The Certificate of Amendment to our Certificate of Incorporation was for the purpose of, among other things, (i) changing our name from "TransBiotec, Inc." to "SOBR Safe, Inc.", (ii) effecting a 1-for-33.26 reverse stock split of our common stock, and (iii) decreasing our authorized common stock from 800,000,000 shares to 100,000,000 shares, and became effective with the State of Delaware on April 24, 2020.

As a result of the reverse stock split effected by our Certificate of Amendment to our Certificate of Incorporation, every 33.26 shares of our outstanding common stock prior to the effect of that amendment were combined and reclassified into one share of our common stock, and the number of outstanding shares of our common stock was reduced from 266,097,657 (pre-split) to approximately 8,000,000 (post-split). No fractional shares were issued in connection with the reverse stock split, and any of our stockholders that would have been entitled to receive a fractional share as a result of the reverse stock split will instead receive one additional share of our common stock in lieu of the fractional share. The reverse stock split will not in itself affect any stockholder's ownership percentage of our common stock, except to the extent that any fractional share is rounded up to the nearest whole share.

At the open of trading on June 8, 2020, our new name and reverse stock split went effective with OTC Markets, and we began trading on the "OTC Pink Current Information" tier of OTC Markets on a post reverse stock split basis. Our ticker symbol for the quotation of our common stock is now "SOBR".

As noted elsewhere herein, we have developed and patented a high technology, state-of-the-art transdermal sensing system that detects alcohol through a person's skin.

The following discussion:

- o summarizes our plan of operation; and
- o analyzes our financial condition and the results of our operations for the three and nine months ended September 30, 2020 and 2019.

This discussion and analysis should be read in conjunction with our financial statements included as part of this Quarterly Report on Form 10-Q, as well as our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019.

Results of Operations for Three Months Ended September 30, 2020 Compared to Three Months Ended September 30, 2019

Summary of Results of Operations

		Three Months Ended September 30,		
	2020	2019		
Revenue	\$ - \$	-		
Operating expenses:				
General and administrative	191,589	89,481		
Stock-based compensation expense	-	-		
Management salaries and consulting fees	352,266	-		
Research and development	152,123	-		
Total operating expenses	695,978	89,481		
Operating loss	(695,978)	(89,481)		
Other income (expense):				
Loss on extinguishment of debt, net	-	-		
Gain on fair value adjustment – derivatives	-	200		
Interest expense	(41,622)	(126,825)		
Amortization of interest - beneficial conversion feature	-	-		
Asset impairment adjustment	<u> </u>	-		
Total other (expense), net	(41,622)	(126,625)		
Net loss	<u>\$ (737,600)</u> <u>\$</u>	(216,106)		

Operating Loss; Net Loss

Our net loss increased by \$521,494 from \$216,106 to \$737,600, from the three-month period ended September 30, 2019 compared to the threemonth period ended September 30, 2020. Our operating loss increased by \$606,497, from \$89,481 to \$695,978 for the same periods. The change in our net loss for the three months ended September 30, 2020, compared to the prior year period, is primarily a result of increases in our management salaries and consulting fees, and research and development, both of which are primarily related to our increased operations and management team in connection with the closing of the transaction with IDTEC. The changes are detailed below.

Revenue

We have not had any revenues since our inception. Since September 2011, we have been involved in the development of our patented SOBR® SafeTM system, including, but not limited to, the developing, testing and marketing of SOBR®CheckTM, our unique alcohol sensor technology. Although we have not had any sales to date, we are planning to be ready to commercialize the SOBR®CheckTM device in the second quarter of 2021.

General and Administrative Expenses

General and administrative expenses increased by \$102,108, from \$89,481 for the three month period ended September 30, 2019 to \$191,589 for the three month period ended September 30, 2020, primarily due to increases in facilities rents, marketing and promotion, accounting and other professional fees.

Management Salaries and Consulting Fees

Management salaries and consulting fees were \$352,266 for the three months ended September 30, 2020. We did not have management salaries and consulting fees in the three months ended September 30, 2019, or such expenses were minimal and included in our general and administrative expenses. The management salaries and consulting fees in 2020 were related to salaries and fees paid to our management and consultants in the three months ended September 30, 2020, which includes our new management team we hired in connection with the transaction with IDTEC.

Research and Development

Research and development was \$152,123 for the three months ended September 30, 2020. We did not have research and development in the three months ended September 30, 2019, or such expenses were minimal and included in our general and administrative expenses. The research and development in 2020 was related to expenses to developing our SOBR® Safe[™] system, including, but not limited to, the developing and testing of SOBRCheck, our unique alcohol sensor technology.

Interest Expense

Interest expense decreased by \$85,203, from \$126,825 for the three month period ended September 30, 2019 to \$41,622 for the three-month period ended September 30, 2020. For both periods these amounts are largely due to the interest on outstanding debt. The decrease between the two periods is largely related to the fact that during 2020 we converted many of the instruments that we were paying interest on in 2019.

Table of Contents

Results of Operations for Nine Months Ended September 30, 2020 Compared to Nine Months Ended September 30, 2019

Summary of Results of Operations

		Nine Months Ended September 30,		
	2020	2019		
Revenue	\$ - 5	5		
Operating expenses:				
General and administrative	400,127	239,97		
Stock-based compensation expense	41,302			
Management salaries and consulting fees	1,103,828			
Research and development	309,403			
Total operating expenses	1,854,660	239,97		
Operating loss	(1,854,660)	(239,97		
Other income (expense):				
Loss on extinguishment of debt, net	(269,144)			
Gain on fair value adjustment – derivatives	60,650	3,40		
Interest expense	(107,253)	(269,61		
Amortization of interest – beneficial conversion feature	(1,407,675)	(5,92		
Asset impairment adjustment	(25,320,555)			
Total other expense, net	(27,043,977)	(272,13		
Net loss	\$(28,898,637) \$	\$ (512,11		

Operating Loss; Net Loss

Our net loss increased by \$28,386,520 from \$512,117 to \$28,898,637, from the nine-month period ended September 30, 2019 compared to the nine-month period ended September 30, 2020. Our operating loss increased by \$1,614,682, from \$239,978 to \$1,854,660 for the same periods. The change in our net loss for the nine months ended September 30, 2020, compared to the prior year period, is primarily a result of an asset impairment expense related to the assets we acquired from IDTEC during the period, as well as us having increases in general and administrative expenses, management salaries and consulting fees, and research in development, all of which are primarily related to our increased operations and management team in connection with the closing of the transaction with IDTEC; offset by a decrease in our interest expense. The changes are detailed below.

Revenue

We have not had any revenues since our inception. Since September 2011, we have been involved in the development of our patented SOBR® SafeTM system, including, but not limited to, the developing, testing and marketing of SOBR®CheckTM, our unique alcohol sensor technology. Although we have not had any sales to date, we are planning to be ready to commercialize the SOBR®CheckTM device in the second quarter of 2021.

General and Administrative Expenses

General and administrative expenses increased by \$160,149, from \$239,978 for the nine month period ended September 30, 2019 to \$400,127 for the nine month period ended September 30, 2020, primarily due to increases in facilities rents, marketing and promotion, accounting and other professional fees.

Stock-Based Compensation Expense

We had stock based compensation expense of \$41,302 for the nine months ended September 30, 2020, compared to \$0 for the nine months ended September 30, 2019. The expense in 2020 was related to the issuance of our common stock as compensation to certain consultants and employees.

Management Salaries and Consulting Fees

Management salaries and consulting fees were \$1,103,828 for the nine months ended September 30, 2020. We did not have management salaries and consulting fees in the nine months ended September 30, 2019, or such expenses were minimal and included in our general and administrative expenses. The management salaries and consulting fees in 2020 were related to salaries and fees paid to our management and consultants in the nine months ended September 30, 2020, which includes our new management team we hired in connection with the transaction with IDTEC.

Research and Development

Research and development was \$309,403 for the nine months ended September 30, 2020. We did not have research and development in the nine months ended September 30, 2019, or such expenses were minimal and included in our general and administrative expenses. The research and development in 2020 was related to expenses to developing our SOBR® Safe[™] system, including, but not limited to, the developing and testing of SOBRCheck, our unique alcohol sensor technology.

Loss on Extinguishment of Debt, Net

Loss on extinguishment of debt, net was \$269,144 for the nine-month period ended September 30, 2020, compared to \$0 for the nine-month period ended September 30, 2019. This increase was due to us converting several notes payable with conversion prices less than the fair market price on the conversion date during the nine months ended September 30, 2020, but none during the nine months ended September 30, 2019.

Gain on Fair Value Adjustment - Derivatives

Gain on fair value adjustment – derivatives was \$60,650 for the nine months ended September 30, 2020, compared to \$3,400 for the nine months ended September 30, 2019. For both periods the amounts are related to us having an outstanding financial instrument that contained an embedded derivative liability. The gain related to the instrument is tied to the price of our common stock.

Interest Expense

Interest expense decreased by \$162,366, from \$269,619 for the nine month period ended September 30, 2019 to \$107,253 for the nine-month period ended September 30, 2020. For both periods these amounts are largely due to the interest on outstanding debt. The decrease between the two periods is largely related to the fact that during 2020 we converted many of the instruments that we were paying interest on in 2019.

Amortization of Interest - Beneficial Conversion Feature

During the nine month period ended September 30, 2020, we had amortization of interest – beneficial conversion feature expense of \$1,407,675 compared to \$5,920 during the nine-month period ended September 30, 2019. The expense in 2020 was related to the amortized discount on a convertible note payable of \$1,485,189. The expense in 2019 was related to the amortized discount on convertible non-related party notes payable.

Asset Impairment Adjustment

We had an asset impairment adjustment of \$25,320,555 in the nine months ended September 30, 2020. We did not have an asset impairment adjustment in the nine months ended September 30, 2019. The asset impairment adjustment in 2020 was related to the value of the stock we issued to IDTEC that was attributed to the robotic assets we acquired from IDTEC versus the value of the assets. When we negotiated the transaction with IDTEC in early-to-mid-2019, we agreed to issue IDTEC 12,000,000 shares of our common stock (post-split) in exchange for the consideration they were transferring to us at the close of the transaction. At the time we negotiated the transaction and signed the Asset Purchase Agreement, our common stock was trading at a lower price than what it was trading at when we closed the transaction and issued the shares. As a result, during the nine months ended September 30, 2020, we impaired the value of the robotic assets we received in the transaction.

Liquidity and Capital Resources for Nine Months Ended September 30, 2020 Compared to Nine Months Ended September 30, 2019

Introduction

During the nine months ended September 30, 2020 and 2019, because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of September 30, 2020 is \$979,641 and our monthly cash flow burn rate is approximately \$125,000. As a result, we do not have short term cash needs, but need to raise additional funds to finance our long term business plans. Our cash needs are being satisfied through proceeds from the sales of our securities and loans from both related parties and third parties. We currently do not believe we will be able to satisfy our cash needs from our revenues for some time, and there is no guarantee we will be successful in the future satisfying these needs through the proceeds generated from the sales of our securities.

Our cash, current assets, total assets, current liabilities, and total liabilities as of September 30, 2020 and as of December 31, 2019, respectively, are as follows:

	s 	eptember 30, 2020	I 	December 31, 2019	_	Change
Cash	\$	979,641	\$	681,759	\$	279,882
Total Current Assets	\$	987,701	\$	690,813	\$	296,888
Total Assets	\$	4,765,210	\$	690,813	\$	4,074,397
Total Current Liabilities	\$	5,139,717	\$	4,283,934	\$	855,783
Total Liabilities	\$	5,139,717	\$	4,283,934	\$	855,783

Our current assets increased as of September 30, 2020, as compared to December 31, 2019, due to us having more cash on hand at September 30, 2020. The increase in our total assets between the two periods is primarily related to our acquisition of assets related to the closing of our Asset Purchase Agreement with IDTEC, LLC.

Our current liabilities increased as of September 30, 2020, as compared to December 31, 2019. This increase was primarily due to increases in accrued dividends payable, preferred stock subscriptions payable, notes payable – related parties, and common stock subscriptions payable, offset by decreases in accounts payable, accrued expenses, accrued interest payable, related party payables and derivative liabilities.

In order to repay our obligations in full or in part when due, we will be required to raise significant capital from other sources. There is no assurance, however, that we will be successful in these efforts.

Sources and Uses of Cash

Operations

We had net cash used for operating activities of \$1,443,783 for the nine-month period ended September 30, 2020, as compared to net cash used for operating activities of \$202,529 for the nine-month period ended September 30, 2019. For the period in 2020, the net cash used in operating activities consisted primarily of our net loss of \$28,898,637 and change in fair value of derivative liability of \$60,650, offset by a loss on debt extinguishment, net of \$269,144, depreciation and amortization of \$133,571, amortization of interest – beneficial conversion feature of \$1,407,675, stock warrants expense of \$8,856, stock options expense of \$343,549, stock-based compensation expense of \$41,302, and asset impairment adjustment of \$25,320,555, and changes in our assets and liabilities of prepaid expenses of \$994, other assets of \$8,680, accounts payable of \$140,906, accrued expenses of \$83,495, accrued interest payable of \$6,697, and related party payables of \$51,976. For the period in 2019, the net cash used in operating activities consisted primarily of our net loss of \$512,117 and change in fair value of derivative liability of \$3,400, offset by amortization of interest-beneficial conversion feature of \$1,202, and stock warrants expense of \$36,103, and changes in our accounts payable of \$2,692, accrued expenses of \$1,393, accrued interest payable of \$123,008, related party payables of \$91,048, stock subscriptions payable of \$1,303, and prepaid expenses of \$3,591.

Investments

We had no cash provided by or used for investing activities during the nine-month period ended September 30, 2020 or September 30, 2019.

Financing

Our net cash provided by financing activities for the nine-month period ended September 30, 2020 was \$1,741,665, compared to \$215,625 for the nine-month period ended September 30, 2020, our net cash from financing activities consisted of proceeds from offering of preferred stock – related parties of \$1,700,000, and proceeds from notes payable – non-related parties of \$41,665. For the nine-month period ended September 30, 2019, our net cash from financing activities consisted of proceeds from notes payable – nelated parties of \$116,625, proceeds from notes payable – non-related parties of \$116,625, proceeds from notes payable – non-related parties of \$39,000.

On January 30, 2020, the World Health Organization ("WHO") announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the "COVID-19 outbreak") and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve as of the date of this filing. Management is actively monitoring the global situation on our financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 outbreak on our results of operations, financial condition, or liquidity for fiscal year 2020. However, if the pandemic continues, it could have an adverse effect on our results of future operations, financial position, and liquidity in year 2020.

Off Balance Sheet Arrangements

We have no off balance sheet arrangements as of September 30, 2020 and December 31, 2019.

ITEM 3 Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, we are not required to provide the information required by this Item.

ITEM 4 Controls and Procedures

(a) Evaluation of Disclosure and Controls Procedures

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Disclosure and control procedures are also designed to ensure that such information is accumulated and communicated to management, including the chief executive officer and chief financial officer, to allow timely decisions regarding required disclosures.

As of September 30, 2020, we carried out an evaluation, under the supervision and with the participation of management, including our chief executive officer (our Principal Executive Officer) and chief financial officer (our Principal Financial Officer), of the effectiveness of the design and operation of our disclosure controls and procedures. In designing and evaluating the disclosure controls and procedures, management recognizes that there are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their desired control objectives. Additionally, in evaluating and implementing possible controls and procedures, management is required to apply its reasonable judgment. We also do not have an audit committee. Based on the evaluation described above, and as a result, in part, of not having an audit committee and having one individual serve as our chief ficancial officer, management has concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were not effective to the same extent as reported in our Annual Report on Form 10-K for the year ended December 31, 2019.

As funds become available to us, we expect to implement additional measures to improve disclosure controls and procedures.

(b) Changes in Internal Controls over Financial Reporting

There was no change in our internal controls over financial reporting that occurred during the period covered by this report, which has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

(c) Officer's Certifications

Appearing as an exhibit to this quarterly report on Form 10-Q are "Certifications" of our Chief Executive and Financial Officer. The Certifications are required pursuant to Sections 302 of the Sarbanes-Oxley Act of 2002 (the "Section 302 Certifications"). This section of the quarterly report on Form 10-Q contains information concerning the Controls Evaluation referred to in the Section 302 Certifications. This information should be read in conjunction with the Section 302 Certifications for a more complete understanding of the topics presented.



PART II - OTHER INFORMATION

ITEM 1 Legal Proceedings

On December 6, 2006, Orange County Valet and Security Patrol, Inc. filed a lawsuit against us in Orange County California State Superior Court for Breach of Contract in the amount of \$11,164. A default judgment was taken against us in this matter. In mid-2013 we learned the Plaintiff's perfected the judgment against us, but we have not heard from the Plaintiffs as of November 2020.

We currently have one outstanding judgment against us involving a past employee of the Company. The matter is under the purview of the State of California, Franchise Tax Board, Industrial Health and Safety Collections. We currently owe approximately \$28,786 plus accrued interest, to our exemployee for unpaid wages under these Orders and are working to get this amount paid off.

In the ordinary course of business, we are from time to time involved in various pending or threatened legal actions. The litigation process is inherently uncertain and it is possible that the resolution of such matters might have a material adverse effect upon our financial condition and/or results of operations. However, in the opinion of our management, other than as set forth herein, matters currently pending or threatened against us are not expected to have a material adverse effect on our financial position or results of operations.

ITEM 1A Risk Factors

As a smaller reporting company, we are not required to provide the information required by this Item.

ITEM 2 Unregistered Sales of Equity Securities and Use of Proceeds

During the three months ended September 30, 2020 we issued the following unregistered securities:

During the three months ended September 30, 2020, we sold 930,000 shares of our 8% Series A-1 Preferred Stock to SOBR Safe, LLC, in exchange for 930,000. The issuance of the shares was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investor was sophisticated, familiar with our operations, and there was no solicitation.

ITEM 3 Defaults Upon Senior Securities

On December 28, 2010, we borrowed \$11,810 from a related party. The note payable carries an interest rate of 0% and matured on December 31, 2012. As of September 30, 2020 this note was in default.

On February 20, 2012, we borrowed \$3,750 from a non-related party. The note payable carries an interest rate of 12% and matured on February 19, 2013. As of September 30, 2020 this note was in default.

On March 20, 2012, we borrowed \$5,433 from a non-related party. The note payable carries an interest rate of 12% and matured on March 19, 2013. As of September 30, 2020 this note was in default.

On September 27, 2013, we borrowed \$15,000 from a non-related party. The note payable carries an interest rate of 9% and matured on December 25, 2013. As of September 30, 2020 this note was in default.

On March 14, 2014, we borrowed \$5,000 from a non-related party. The note payable carries an interest rate of 10% and matured on September 14, 2014. As of September 30, 2020 this note was in default.

On July 31, 2015, we borrowed \$2,500 from a non-related party. The note payable carries an interest rate of 10% and matured on November 28, 2015. As of September 30, 2020 this note was in default.

ITEM 4 Mine Safety Disclosures

There have been no events which are required to be reported under this Item.

ITEM 5 Other Information

IDTEC Asset Purchase Agreement.

On June 5, 2020, we closed the transaction (the "Transaction") that was the subject of that certain Asset Purchase Agreement dated May 6, 2019 (and Amendment No. 1 dated March 9, 2020, together the "APA") with IDTEC, LLC ("IDTEC"), under which IDTEC agreed to provide personnel, experience, and access to funding to assist with the development of our SOBR device, as well as to sell to us certain robotics assets, which our management believes are synergistic with our current assets, in exchange for 12,000,000 shares of our common stock after giving effect to the reverse stock split effected in connection with closing the transaction. The closing of the Transaction was subject to several conditions precedent, primarily: (i) we had to be current in our reporting requirements under the Securities Exchange Act of 1934, as amended, (ii) we had to complete a reverse stock split of our common stock such that approximately 8,000,000 shares were outstanding immediately prior to closing the transaction, (iii) we could only have outstanding convertible instruments as set forth in the APA, (iv) our authorized common stock had to be reduced to 100,000,000 shares, and (v) we could not have more than approximately \$125,000 in current liabilities. Effective with the closing of the transaction all of the closing conditions had been met, modified or waived by IDTEC, and we issued the 12,000,000 shares to IDTEC in exchange for IDTEC providing access to personnel, experience, funding to assist with the development of our SOBR device, as well as the robotics assets. The description of the APA set forth in this report is qualified in its entirety by reference to the full text of that document and the amendment, which are attached hereto as Exhibits 10.1 and 10.12, respectively.

In advance of closing the Transaction, IDTEC and a few other affiliated parties (i) loaned funds directly to us, (ii) spent funds for the general costs related to the Transaction, and/or (iii) spent funds to further develop and enhance the current SOBR product. As a result of closing the Transaction, all the funds spent by IDTEC for any reason related to the Transaction were turned into a convertible promissory note. This note totaled approximately \$1,485,000 at closing, carried a simple interest rate of 10% per annum, is due upon demand, and may be convertible into shares of our common stock at \$0.50 per share (after giving effect to the reverse stock split and subject to anti-dilution protection against any future securities we may issue at an effective price of less than \$0.50 per share) at the discretion of the holder. The repayment of this promissory note is secured by a first priority security lien or security interest in our patents, trademarks, trademarks and other intellectual property described in Exhibit A of the promissory note. The convertible promissory note we issued is in the form attached hereto as Exhibit 10.13.

As noted above, in connection with the closing of the Transaction, both companies had certain closing conditions under the APA that had to be met. At closing, some of the closing conditions under the APA were either waived and/or modified by the parties. In order to document those modifications and waivers, we entered into a Waiver Under Asset Purchase Agreement and Post-Closing Covenant Agreement with IDTEC. The description of the Waiver Under Asset Purchase Agreement and Post-Closing Covenant Agreement set forth in this report is qualified in its entirety by reference to the full text of that document, which is attached hereto as Exhibit 10.14.

One of the closing conditions that was the subject of the Waiver Under Asset Purchase Agreement and Post-Closing Covenant Agreement was the requirement that we have under \$125,000 in permitted liabilities (not including aged liabilities) after closing of the Transaction. At closing we had approximately \$158,000 in non-permitted liabilities under the APA. As a result, we issued a Warrant to Purchase Common Stock to IDTEC (the "Warrant"), under which IDTEC will purchase up to 320,000 shares of our common stock (post-split) at an exercise price of \$0.50 per share, if either (i) we are forced to pay a non-permitted liability, then we may force IDTEC to exercise the Warrant and pay the exercise price to pay the non-permitted liability, but only in an amount sufficient to pay the non-permitted liability (which are listed on Exhibit A of the Warrant), or (ii) if IDTEC otherwise elects to exercise the Warrant and acquire some or all of the shares underlying the Warrant. The Warrant expires five years after the date of issuance. The description of the Warrant set forth in this report is qualified in its entirety by reference to the full text of that document, which is attached hereto as Exhibit 10.15.

Table of Contents

ITEM 6 Exhibits

Item No.	Description
<u>3.1 (1)</u>	Articles of Incorporation of Imagine Media, Ltd.
<u>3.2 (2)</u>	Articles of Amendment to Articles of Incorporation to TransBiotec, Inc.
<u>3.3 (3)</u>	Certificate of Amendment to Certificate of Incorporation filed with the State of Delaware on May 25, 2017
<u>3.4 (6)</u>	Amended and Restated Bylaws of SOBR Safe, Inc.
<u>3.5 (10)</u>	Certificate of Amendment to Certificate of Incorporation of TransBiotec, Inc. changing name to SOBR Safe, Inc., effecting 1-for-33.26 reverse stock split and decreasing authorized common stock to 100M shares
<u>10.1 (4)</u>	Asset Purchase Agreement dated May 6, 2019 between IDTEC, LLC and TransBiotec, Inc.
<u>10.2 (5)</u>	Common Stock Purchase Agreement with Charles Bennington dated August 23, 2019
<u>10.3 (5)</u>	Share Exchange Agreement with Michael Lanphere dated August 23, 2019
<u>10.4 (5)</u>	Share Exchange Agreement with Vernon Justus dated August 23, 2019
<u>10.5 (5)</u>	Debt Conversion and Common Stock Purchase Agreement with Michael Lanphere dated August 23, 2019
<u>10.6 (5)</u>	Debt Conversion and Common Stock Purchase Agreement with Devadatt Mishal dated August 23, 2019
<u>10.7 (6)</u>	TransBiotec, Inc. 2019 Equity Incentive Plan
<u>10.8 (6)</u>	Employment Agreement with Kevin Moore dated October 25, 2019
<u>10.9 (8)</u>	Amended Employment Agreement with Kevin Moore dated November 26, 2019
<u>10.10 (6)</u>	Employment Agreement with David Gandini dated October 25, 2019
<u>10.11 (7)</u>	Series A-1 Preferred Stock Purchase Agreement by and between TransBiotec, Inc. and SOBR SAFE, LLC dated December 12, 2019 (with Series A-1 Preferred Stock Certificate of Designation attached)
<u>10.12 (9)</u>	Amendment No. 1 to Asset Purchase Agreement dated March 23, 2020 by and between IDTEC, LLC and TransBiotec, Inc.
<u>10.13 (10)</u>	Form of Convertible Promissory Note Issued to IDTEC, LLC at Close of Asset Purchase Transaction
<u>10.14 (10)</u>	Waiver Under Asset Purchase Agreement and Post-Closing Covenant Agreement dated June 5, 2020 by and between IDTEC, LLC and TransBiotec, Inc.
10.15 (10)	Warrant to Purchase Common Stock dated June 5, 2020 issued to IDTEC, LLC

Table of Contents

<u>31.1*</u>	Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer (filed herewith)
<u>31.2*</u>	Rule 13a-14(a)/15d-14(a) Certification of Chief Accounting Officer (filed herewith)
32.1*	Section 1350 Certification of Chief Executive Officer (filed herewith).
32.2*	Section 1350 Certification of Chief Accounting Officer (filed herewith).
101.INS **	XBRL Instance Document
101.SCH **	XBRL Taxonomy Extension Schema Document
101.Self	XBRL Taxonomy Extension Calculation Linkbase Document
	·
101.DEF **	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB **	XBRL Taxonomy Extension Label Linkbase Document
101.PRE **	XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith.

** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

(1) Incorporated by reference from our Registration Statement on Form SB-2, filed with the Commission on January 31, 2008

- (2) Incorporated by reference from our Registration Statement on Form S-1, filed with the Commission on November 6, 2012
- (3) Incorporated by reference from our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Commission on February 6, 2019
- (4) Incorporated by reference from our Current Report on Form 8-K, filed with the Commission on May 14, 2019.
- (5) Incorporated by reference from our Current Report on Form 8-K, filed with the Commission on September 10, 2019.
- (6) Incorporated by reference from our Current Report on Form 8-K, filed with the Commission on November 19, 2019
- (7) Incorporated by reference from our Current Report on Form 8-K, filed with the Commission on December 23, 2019
- (8) Incorporated by reference from our Annual Report on Form 10-K, filed with the Commission on April 17, 2020
- (9) Incorporated by reference from our Quarterly Report on Form 10-Q for the period ended March 31, 2020, filed with the Commission on May 26, 2020
- (10) Incorporated by reference from our Current Report on Form 8-K filed with the Commission on June 11, 2020

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SOBR Safe, Inc.

Dated: November 16, 2020

By: /s/ Kevin Moore

Kevin Moore Its: Chief Executive Officer and Principal Executive Officer

Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer

I, Kevin Moore, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q of SOBR Safe, Inc.;
- Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exhibit Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 16, 2020

By: /s/ Kevin Moore

Kevin Moore Chief Executive Officer and Principal Executive Officer

Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer

I, David Gandini, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q of SOBR Safe, Inc.;
- Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exhibit Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 16, 2020

By: <u>/s/ David Gandini</u>

David Gandini Chief Financial Officer and Chief Accounting Officer

CERTIFICATION PURSUANT TO 18 USC, SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of SOBR Safe, Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2020, as filed with the Securities and Exchange Commission on or about the date hereof (the "Report"), I, Kevin Moore, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 16, 2020

By: <u>/s/ Kevin</u> Moore

Kevin Moore Chief Executive Officer and Principal Executive Officer

A signed original of this written statement required by Section 906 has been provided to SOBR Safe, Inc. and will be retained by SOBR Safe, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

CERTIFICATION PURSUANT TO 18 USC, SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of SOBR Safe, Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2020, as filed with the Securities and Exchange Commission on or about the date hereof (the "Report"), I, David Gandini, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 16, 2020

By: /s/ David Gandini

David Gandini Chief Financial Officer and Chief Accounting Officer

A signed original of this written statement required by Section 906 has been provided to SOBR Safe, Inc. and will be retained by SOBR Safe, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.